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Development of an Ecological Model to Predict Risk for Acquisition of Clostridium 
difficile-Associated Diarrhea During Acute Care Hospitalization 
Susan Elaine Steele 
 
ABSTRACT 
 
Background:  The traditional model of infection control has failed to stop the spread of 
emerging infectious diseases such as Clostridium difficile-associated diarrhea (CDAD) in 
the acute care environment.  Ecological models, which rely upon identification of 
susceptible hosts, offer an alternative to the prevention of deadly outbreaks.  Previous 
epidemiological research has identified a number of risk factors associated with CDAD.  
Utilization of this body of research by nurses is limited due to methodological issues that 
introduce bias and confounding, and use of variables that have limited meaning to the 
practicing clinical nurse. 
Aim:  The aim of this study was to develop an ecological model useful for nurses in 
predicting the susceptibility of individuals to CDAD during an acute care hospital stay.   
Method:  A case-control study compared 66 cases with CDAD to 66 controls matched for 
the temporal and spatial risk factors of hospital admission date and geographic nursing 
care unit within the institution.  The two subject groups were compared on variables of 
age, antibiotic burden, laxative or bowel preparation exposure, nutritional status, gastric 
acid suppression therapy, enteral feeding exposure, and severity of illness as measured on 
the Horn Severity of Illness index.  All subjects were hospitalized between January 1, 
2000 and December 31, 2006. 
vii 
Results:  On univariate analysis, age, severity of illness, serum albumin levels, length of 
exposure, and proton pump inhibitor drug burden were significantly associated with 
CDAD status.  Following multivariate analysis, only severity of illness, length of 
exposure, and decreased antibiotic drug burden were significantly associated with the 
development of hospital-acquired CDAD. 
Conclusions:  This study supports the use of an ecological perspective in identifying risk 
factors and interventions to prevent the future spread of this infectious disease. 
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Chapter One 
Introduction 
Clostridium difficile (C. difficile) is a gram-positive, spore-forming anaerobe, first 
identified in 1935 in the normal enteric flora of infants (Hall & O'Toole, 1935).  A case-
series analysis published in the early 1960’s discounted a serious health threat from C. 
difficile, concluding that either the toxin was not produced within the human body or that 
humans did not exhibit a marked sensitivity to the toxins produced by the bacteria (Smith 
& King, 1962).  However, discovery of a link between antibiotic-associated 
pseudomembranous colitis and a toxin-producing strain of a Clostridium species in the 
1970’s clearly established the organism as a human pathogen and triggered a series of 
investigations associating various antibiotics with the development of the disease 
(Bartlett, 2004). 
By 1980, C. difficile- associated diarrhea (CDAD) was identified as a serious 
nosocomial infection (Mulligan, George, Rolfe, & Finegold, 1980; Peikin, Galdibini, & 
Bartlett, 1980).  Since the 1980’s, research has expanded understanding that C. difficile 
infection occurs in a continuum extending from asymptomatic carriage to fulminating 
pseudomembranous colitis.  Toxigenic strains of C. difficile have been isolated from 
feces of healthy adults not recently exposed to antibiotics, with reported prevalence 
ranging from 4.2% to 53.3% (Iizuka et al., 2004; Kato et al., 2001; Nakamura et al., 
1981), indicating that transmission and carriage of the organism may occur undetected 
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among the general population, as well as among institutionalized individuals.  Although 
such colonization is believed to be transient in most cases, there is evidence that 
persistent C. difficile colonization does occur in some individuals (Ozaki et al., 2003).  
Among hospital patients, colonization followed by an IgG antibody response has been 
associated with a decreased risk of CDAD acquisition after adjustment for age, sex and 
disease severity (Kyne, Warny, Qamar & Kelly, 2000), and an acquired immune response 
to toxin A following an episode of CDAD is believed to be protective against recurrence 
of diarrhea (Kyne, Warny, Qamar & Kelly, 2001). 
There is indication that increasing numbers of persons are experiencing the most 
severe outcomes of C. difficile infection including pseudomembranous colitis and death 
(Dallal et al., 2002; Frost, Craun, & Calderon, 1998; Morris et al., 2002; Pepin et al., 
2004),.  Most recently, a change in the epidemiologic pattern of the disease has been 
noted, including geographically dispersed outbreaks (Krausz et al., 2005; Loo et al., 
2005; McDonald et al., 2005; Warny et al., 2005), an increasingly virulent strain of the 
organism  (Morris et al., 2002; Pepin et al., 2004; Pepin, Valiquette, & Cossette, 2005), 
and susceptibility of populations previously believed to be low risk for acquisition of 
CDAD (Centers et al., 2005).  Because persons who develop nosocomial CDAD 
experience a more than 50% increase in hospital costs, increased length of stay and a 
significantly higher mortality rate, the burden of this disease threatens the health care 
system (Kyne, Hamel, Polavaram, & Kelly, 2002; Miller, Hyland, Ofner-Agostini, 
Gourdeau, & Ishak, 2002). 
Investigations in prevention of CDAD have included antibiotic restriction 
policies, vaccine development (Kotloff et al., 2001; Sougioultzis et al., 2005), and dietary 
3 
modulation of intestinal microflora.  Dietary interventions have included use of 
prebiotics, non-digestible fiber agents that ferment and foster growth of normal flora, 
probiotics, live organisms found in healthy flora, and synbiotics, a combination of a 
prebiotic and probiotic agent (Bengmark, 2003; Collins & Gibson, 1999).  These research 
efforts, while somewhat promising, currently lack sufficient evidence to support their use, 
and prevention of CDAD is dependent upon traditional infection control processes such 
as hand hygiene, isolation, and environmental decontamination. 
Epidemiological and biomedical models for the prevention of infectious diseases 
are based upon identification, and destruction or elimination of the causative organism.  
Such an approach ignores the evolutionary potential of an enormously diverse 
prokaryotic domain (Galvani, 2003; Purssell, 2005a, , 2005b) as well as the 
environmental and social factors in the modern age that have altered the relationship 
between man and microbe (de Albuquerque Possas, 2001; McMichael, 2004; Waldvogel, 
2004).  In contrast, an ecological model of infectious disease offers an understanding of 
the way temporal and spatial relationships between host and pathogen can be altered to 
reduce the risk of disease (Koren & Crawford-Brown, 2004).   
The human intestine can be described as a complex ecosystem, comprised of a 
constantly resurfacing organ playing host to both resident and transient microbes existing 
in a state of mutualism (Xu & Gordon, 2003).  In healthy adults, the indigenous bacteria 
within the intestine control pathogenic invasion via colonization resistance (van der 
Waaij, 1989).  In return, the host provides mucus, shed epithelial cells, and ingested food 
particles which allow the bacteria to thrive in a physiologic bioreactor (Backhed, Ley, 
Sonnenburg, Peterson, & Gordon, 2005). 
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CDAD represents a disruption of the intestinal ecosystem, manifested by an 
increase in enterococci (Hopkins & MacFarlane, 2002; Ozaki et al., 2003) a decline in 
Bifidobacteria and Bacteroides colonization (Hopkins & MacFarlane, 2002), and 
proliferation of C. difficile.  A number of case series reported successful treatment of 
recurrent  CDAD by rectal or nasogastric administration of donor stool, further 
supporting the importance of a healthy intestinal ecosystem in combating the disease 
(Aas, Gessert, & Bakken, 2003; Bowden, Mansberger, & Lykins, 1981; Eiseman, Silen, 
Bascom, & Kauvar, 1958; Persky & Brandt, 2000; Schwan, Sjolin, Trottestam, & 
Aronsson, 1984; Tvede & Rask-Madsen, 1989).   Restoration of the normal colonic flora 
has been the focus of increasing research regarding a number of diseases including C. 
difficile, driven by advances in genomics and global awareness of emerging infectious 
diseases (McMichael, 2004; Rastall et al., 2005).  However, there remains a lack of 
clinical trial data to help target populations most likely to benefit and to substantiate the 
specific agents appropriate for prevention and treatment of CDAD. 
Alteration in intestinal ecology can effect diarrhea through disturbances in 
motility, defects in the immune system, and failure of colonization resistance (Hawrelak 
& Myers, 2004).   The development and maintenance of the normal intestinal ecosystem 
is influenced by several factors, including age, dietary intake, and systemic drug therapy.  
Indigenous bacteria begin to form colonies at the time of birth as a result of 
exposure to maternal bacteria in the vagina, and within the first few days of life, the 
diversity of the fecal flora changes rapidly (Park et al., 2005).    Early in life, C. difficile 
colonization is common, and C. difficile has been demonstrated within the intestinal 
microbiota of healthy infants in hospital, home, and day care environments (Larson, 
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Barclay, Honour, & Hill, 1982; Matsuki et al., 2005; Park et al., 2005; Penders et al., 
2005; Stark, Lee, & Parsonage, 1982).  As an individual matures, changes in bacterial 
composition result in greater species diversity accompanied by a decline in C. difficile 
(Hopkins & MacFarlane, 2002; Hopkins, Sharp, & Macfarlane, 2001).  However, as an 
individual approaches advanced age, a decline in Bifidobacteria and an increase in 
enterococci occurs (Hebuterne, 2003; Hopkins & MacFarlane, 2002; Hopkins, Sharp, & 
Macfarlane, 2001). 
Dietary intake plays a significant role in fecal bacterial colonization.  Ingestion of 
non-digestible carbohydrates provides nutrition to support the production of various 
bacterial species.  Both naturally occurring and experimental-supplement induced dietary 
intake of oligosaccharides results in an increase in fecal Bifidobacteria levels (Boehm et 
al., 2004; Gibson, Beatty, Wang, & Cummings, 1995; Langlands, Hopkins, Coleman, & 
Cummings, 2004; Penders et al., 2005; Stark, Lee, & Parsonage, 1982) and the increase is 
dose-dependent (Bouhnik et al., 1999).  Oligosaccharide supplementation resulted in a 
decrease in C. difficile colonization both in vitro (Hopkins & MacFarlane, 2003) and in 
healthy adults receiving the supplement during a  course of an oral cephalosporin 
antibiotic (Orrhage, Svante, & Nord, 2000).   
Hospitalization for illness or injury often requires nutritional support via enteral 
nutrition (tube feeding).  A common gastrointestinal complication of enteral feeding is 
diarrhea, with reported incidence ranging from 2.3% to 38% among general hospital 
populations and as high as 68% among critically ill adults (Cataldi-Betcher, Seltzer, 
Slocum, & Jones, 1983; Elpern, Stutz, Peterson, Gurka, & Skipper, 2004; Heimburger, 
Sockwell, & Geels, 1994; Homann, Kemen, Fuessenich, Senkal, & Zumtobel, 1994; 
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Montejo, 1999; Pancorbo-Hidalgo, Garcia-Fernandez, & Ramirez-Perez, 2001; C. Smith 
et al., 1990).  Suggested causes for tube-feeding-associated diarrhea include 
hypoalbuminemia, formula intolerance, concomitant use of sorbitol-containing elixir 
medications (Eisenberg, 2002) and colonic response to a non-physiologic form of feeding 
(Bowling & Silk, 1998).  However, enteral nutrition also results in a decrease in 
anaerobic and an increase in aerobic bacteria in feces (Schneider et al., 2000; Whelan, 
Judd, Preedy, & Taylor, 2004), a trend that may be altered by formulas supplemented 
with fiber (Nakao et al., 2002).   Enteral feeding and the presence of nasogastric or 
percutaneously inserted enteral feeding tubes have been found to have significant 
association with the acquisition of CDAD (D. Z. Bliss et al., 1998; Komatsu et al., 2003; 
Kyne et al., 1999; Lai, Melvin, Menard, Kotilainen, & Baker, 1997). 
Illness and medical treatment also is associated with alteration in the gut 
ecosystem.  Although antibiotics have received the most attention in investigations, both 
acid suppressive and laxative medications also have been implicated in altering colonic 
flora.  The effect of antibiotics upon intestinal microflora varies both between and within 
drug categories.  A structured research review of papers published between 1991 and 
2000 identified a decrease in obligate anaerobes such as Bacteroides, Bifidobacterium, 
and Lactobacillus, an increase in facultative anaerobes such as Enterococcus, and 
Streptococcus, and an increase in aerobic organisms such as Pseudomonas (Sullivan, 
Edlund, & Nord, 2001) as common antibiotic effects.  This same review identified a large 
number of cephalosporin agents associated with overgrowth of C. difficile.  More recent 
publications report similar findings of floral suppression and proliferation of competing 
bacteria (Bartosch, Fite, Macfarlane, & McMurdo, 2004; Buhling, Radun, Muller, & 
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Malfertheiner, 2001; Hawrelak & Myers, 2004; Madden et al., 2005; Monreal, Pereira, & 
Lopes, 2005; Takesue et al., 2002).  The ecosystem changes which occur as a result of 
antibiotic usage are not immediately reversible with cessation of antibiotic therapy, and it 
may take more than a month to return to pretreatment levels of dominant microbial 
species (Buhling, Radun, Muller, & Malfertheiner, 2001; De La Cochetiere et al., 2005). 
The use of gastric acid suppressive medications has been associated with the 
development of CDAD in residents of long-term care facilities, as well as hospitalized 
and community-based individuals (Al-Tureihi, Hassoun, Wolf-Klein, & Isenberg, 2005; 
Cunningham, Dale, Undy, & Gaunt, 2003; Dial, Alrasadi, Manoukian, Huang, & 
Menzies, 2004; Dial, Delaney, Barkun, & Suissa, 2005; L.V. McFarland, Surawicz, & 
Stamm, 1990).  The exact effect of acid suppressive agents upon intestinal microflora is 
not known.  It is hypothesized that suppression of gastric acid allows an increased 
number of potential pathogens to survive transition from stomach to intestine (Donskey, 
2004). 
Laxative drugs also may alter intestinal flora.  Chronic constipation in adults is 
associated with alterations in colonic ecology as compared to healthy controls.  
Treatment with both bisacodyl and lactulose result in normalization of the flora (Bouhnik 
et al., 2004; Khalif, Quigley, Konovitch, & Maximova, 2005; Zoppi et al., 1998), but 
polyethylene glycol-4000 does not exert the same ecological effect (Bouhnik et al., 
2004).  Lactulose in particular has been found to promote the growth of lactic acid 
bacteria and Bifidobacteria (Salminen & Salminen, 1997), and to suppress the 
proliferation of potential pathogens such as Clostridium difficile (Ballongue, Schumann, 
& Quignon, 1997; Ito et al., 1997).  Laxative usage is a potential confounder in research 
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regarding CDAD, since both the disease and the drug may alter stool consistency and 
frequency. 
Problem Statement 
 Through previous research, a number of ecological risk factors pertinent to 
hospitalized adults have been identified for the development of CDAD.  These risk 
factors include advanced age, use of tube feeding, malnutrition, severity of illness, and 
the use of medications that alter the intestinal flora, including gastric acid suppressant 
agents, antibiotics, and cathartics. 
The purpose of this study was to develop and test an ecological model useful to 
nurses in predicting risk for the development of Clostridium difficile-associated diarrhea.  
It was anticipated that the model would serve three purposes:  (1) serve as a foundation 
for development of a valid and reliable risk assessment tool (2) aid in the design of future 
clinical trials of nurse-directed prevention strategies and (3) assist clinicians in modifying 
infection control practices in institutional settings when caring for high-risk individuals. 
Hypotheses 
This study is designed to test a hypothesis about the risk factors for development 
of hospital-acquired CDAD: 
H1:  Severity of illness, length of exposure, and malnutrition, are significant 
predictors for the development of CDAD among cases as compared to C. difficile-
negative controls with diarrhea when matched for admission date, and geographic 
unit of hospital, and after controlling for the effects of age, tube feeding, cathartic 
administration, antibiotic therapy, and acid suppression therapy. 
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Definition of Terms 
Diarrhea.   
For purposes of this study, diarrhea was defined as at least three stools within a 24 
hour period documented within the medical record as “liquid”, “loose”, “unformed”, or 
“diarrhea”, or 250 milliliters of liquid stool collected via a colostomy, adhesive fecal 
incontinence collection pouch, or a rectally inserted bowel management tube, or at least 
1500 milliliters of liquid stool from an ileostomy pouch.   
Clostridium difficile-associated diarrhea.   
Diarrhea occurring concurrently with or within 7 days of a positive cytotoxin 
assay, stool culture, or endoscopic examination consistent with pseudomembranous 
colitis. 
Antibiotic burden.   
Antibiotic burden was defined as the sum of the average daily maintenance doses 
of oral or intravenously administered antibiotics received by the patient during the risk 
period.  These average daily doses were determined by use of the World Health 
Organization Defined Daily Dose system (WHO Collaborating Centre for Drug 
Statitistics Methodology, 2007)  
Length of exposure/risk period.   
The length of exposure, or risk period, for this study commenced on the date of 
admission to the acute care hospital and ended on the date that a stool specimen was 
submitted for Clostridium difficile testing. 
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Significance to Nursing 
Nurses spend the most time in the physical proximity of infected and potentially 
vulnerable patients within the health care system.  Because nursing role functions include 
assistance with toileting, they are often able to predict a positive Clostridium difficile 
cytotoxin test result based upon knowledge of a patient’s prior antibiotic use and the 
presence of a distinctive fecal odor (Johansen, Vasishta, Edison, & Hosein, 2002).  
Nurses have been implicated as possible agents in the spread of the disease in hospitals 
(Chang & Nelson, 2000; Perry, Marshall, & Jones, 2001), and are responsible in 
institutional settings for supervising the environmental decontamination of individual 
patient rooms and geographic units, critical to the prevention of disease transmission 
(Chang & Nelson, 2000; Kroker, Bower, & Azadian, 2001; Mayfield, Leet, Miller, & 
Mundy, 2000; Verity, Wilcox, Fawley, & Parnell, 2001; Wilcox et al., 2003).    
Diarrhea is a frequent cause of fecal incontinence in acutely-ill hospitalized adults 
(Bliss, Johnson, Savik, Clabots, & Gerding, 2000), requiring increased nursing care hours 
and supplies for skin cleansing, treatment of skin breakdown, and linen changes.  CDAD 
is now recognized as the most common type of infectious nosocomial diarrhea 
(McFarland, 1995).  Outbreaks of CDAD have been well-documented (Blot et al., 2003; 
Johnson et al., 1999; Kuijper et al., 2001) and reported incidence rates of nosocomial 
CDAD range from 0.19  to 6.8 per 100 hospital admissions (Dial, Alrasadi, Manoukian, 
Huang, & Menzies, 2004; Thomas, Stevenson, Williamson, & Riley, 2002).  A global 
shortage of qualified professional nurses compromises containment of emerging 
infectious diseases in health care settings (Stone, Clarke, Cimiotti, & Correa-de-Araujo, 
2004).   
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Traditional methods of preventing the spread of infectious diseases within 
hospitals have not proven sufficient to combat emerging infections such as CDAD.  An 
alternative ecological approach to disease prevention requires change in nursing practice 
to decrease the impact of the organism upon human hosts.  By strengthening the natural 
flora of the hospitalized individual and increasing the spatial and temporal distance 
between susceptible persons and potentially infectious organisms, the degree of harm 
caused by the organism can be reduced (Purssell, 2005a).  Table 1 compares and 
contrasts the biomedical and ecological approaches to infectious disease prevention.   
Table 1 
Prevention and Treatment of Infectious Diseases: Traditional Versus Ecological Models  
 Model 
 
Aspect of Care Traditional  
 
Ecological  
Detection Identification of persons with 
disease 
Identification of persons 
susceptible to disease 
Symptom treatment Treat symptoms Treat only symptoms that have 
no benefit for the host 
Chemoprophylaxis Prophylactic administration of 
antimicrobial agents 
Administration of 
biotherapeutic agents to 
maintain or restore host flora 
Isolation Isolate persons with disease Isolate persons with symptoms 
and susceptible persons based 
on level of susceptibility and 
degree of immunosuppression 
Environmental 
Controls 
Uniform environmental 
cleaning protocols to remove 
pathogens 
In addition to environmental 
cleaning protocols, increase 
spatial and temporal intervals 
between susceptible host and 
pathogen contact 
 
Note.  Adapted from Pursell, 2005a and Pursell, 2005b. 
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Key differences in the two approaches lie in the detection of susceptibility to 
disease and the modulation of host flora to combat the growth of potentially pathogenic 
microbial species.  To utilize such an approach, nurses require a simple and reliable risk 
assessment tool for estimating susceptibility to CDAD.  The development of a predictive 
model would enable further development of such a tool. 
Summary 
CDAD is a serious infection that can be understood as a disturbance of the 
intestinal ecology.  Identification of the factors that make an individual most susceptible 
to CDAD would enable the design of infection control interventions based on ecological 
principles to decrease the extent of harm caused by this microorganism.  Advancing age, 
severity of illness, diet, and use of antibiotic, acid suppressive and cathartic medications 
have been identified as factors that disrupt the normal intestinal ecology and may 
promote the development of CDAD. 
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Chapter Two 
Review of the Literature 
By virtue of its increasing incidence, virulence and global geographic range, 
CDAD is considered an emerging infectious disease.  Changes within the environment 
and in human ecology are precipitating factors which account for the emergence of most 
such diseases (de Albuquerque Possas, 2001; Lederberg, Shope, & Oaks, 1992; 
McMichael, 2004; Morse, 1995).  Changes in human demographics and behavior 
increase both exposure to infectious agents and susceptibility to their deleterious effects.  
This chapter will present a review of the analytic epidemiology research literature 
identifying human demographic and behavioral risk factors for the development of C. 
difficile-associated diarrhea.  An ecological model to guide the study of CDAD will be 
developed.   
A literature search was conducted in both Medline and CINAHL electronic 
databases for the years 1995 through March 2006.  The keywords “Clostridium difficile” 
was paired using the Boolean connector “AND” with each of the following keywords: 
“risk factors”, “age”, “antibiotic”, “tube feeding”, “laxative OR bowel preparation”, 
“severity of illness” and “acid suppression”.  Articles were limited to those published in 
the English language, and studies concerning adult subjects in a hospital or institutional 
setting, designed to understand risk factors for an initial episode of Clostridium difficile-
associated diarrhea.  The electronic search was supplemented with ancestral retrievals for 
a final yield of 73 publications. 
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The sample included one meta-analysis and one structured literature review.  The 
remaining 71 original research reports included 36 case-control studies, 13 prospective 
and nine retrospective cohort studies, three clinical trials, and ten descriptive studies.  The 
majority of the studies in the review were conducted in North America and Europe; 
however, the sample did include studies conducted in Asia and Oceania-Australasia, 
indicating potential for some genetic diversity among the study populations.  Subjects 
were being treated both medically and surgically for a variety of conditions including 
cancer, pneumonia, complications of human immunodeficiency virus infection, and 
cardiac disease. 
Qualitative Assessment 
To systematically assess the quality of the clinical trial, case-control and cohort 
study publications, a criterion-based checklist was adapted (Downs & Black, 1998).  The 
original checklist was modified based upon important domains and elements for 
systematic review advocated by the Agency for Healthcare Research and Quality (West 
et al., 2002).   
The checklist items were entered into an Excel spreadsheet and each publication 
was subjected to the same questions regarding quality of the published report, internal 
validity and external validity of the research methods described, and disclosure of 
funding source.  Publications were assigned a code of one if the element was present 
within the publication and a code of zero if the element was absent.  Thus, the both the 
number and the percentage of publications that met each of the specified criteria could be 
calculated.  The ten descriptive studies were not subjected to this checklist assessment, as 
the conduct of the studies and the method of reporting were incompatible with this tool.   
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These publications, along with the two systematic reviews, were used to help further 
shape understanding of the ecological concepts.  Table 2 summarizes the results of this 
qualitative review of the publications. 
Table 2 
Number and Percent of Studies Meeting Evaluation Criteria 
Checklist Item Number  %  
Reporting Quality   
 Was a hypothesis, aim, or study objective stated? 52 85.25 
 Were the main findings of the study clearly described? 55 90.16 
External Validity   
 Were inclusion and exclusion criteria used to determine 
eligibility for participation in the study? 
20 32.79 
  Were only inclusion criteria, and not exclusion criteria, 
identified in the paper? 
20 32.79 
 Were the subjects representative of the entire population from 
which they were recruited? 
40 65.57 
Internal Validity (bias and confounding)   
 Was an attempt made to blind subjects to the intervention they 
have received (clinical trials, n=3)? 
1 33.33 
 Was an attempt made to blind those measuring the main 
outcomes of the intervention (clinical trials, n=3)? 
1 33.33 
 Were the statistical tests used to assess the main outcomes 
appropriate to the research question? 
55 90.16 
 Were the measurements used to assess the main outcome 
accurate (valid and reliable)? 
52 85.25 
 Were subjects in different intervention groups (trials and cohort 
studies) or were cases and controls (case-control studies) 
recruited from the same population? 
32 52.46 
 Were study subjects randomized to intervention groups 
(clinical trials?) 
1 33.33 
 Was there adequate adjustment for confounding in the 
statistical analysis from which the main findings were drawn? 
35 57.38 
Disclosure   
 Was the funding source for the study identified? 13 21.31 
 
Report quality 
Within this body of literature, reporting quality was high for two of the criteria 
considered.  The majority of the published reports included an explicit or implied 
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hypothesis, aim or objective for the study (85%), and clearly described the main findings 
of the study (90%).  All three interventional studies clearly described the intervention.  
However, only 16 (26%) of the observational studies clearly reported a method of 
measurement for the exposures or risk factors of interest.   
Internal validity 
Assessment of internal validity included factors such as blinding and 
randomization for the interventional studies, statistical analysis methods, and presence or 
absence of bias.   
Of the three interventional studies, only one blinded both subjects and those 
measuring outcomes to the group assignment (Cleary et al., 1998).  The other 
interventional studies used no blinding in the study design (Rao, Rao, & Starke, 2003; 
Settle, Wilcox, Fawley, Corrado, & Hawkey, 1998).  Cleary et al. also was the only study 
to include randomization in the assignment of subjects to intervention groups. 
Statistical analysis methods used to assess study data were appropriate to the 
research question and design in most studies (86%).  Although a number of the 
observational studies considered more than one risk factor for the development of 
CDAD, only 35 studies (57%) described adequate adjustment for the effects of 
confounding in discussing the main findings of the studies.  Twenty-five studies (41%) 
used multivariate statistical techniques in an effort to control the effects of confounding 
during data analysis.  The most frequently reported type of multivariate data analysis 
strategy was stepwise logistic regression.  Results of stepwise procedures in multivariate 
analysis are easily misinterpreted because predictors may be excluded which are, in fact, 
highly correlated with the outcome of interest (Tabachnick & Fidell, 2001).  To minimize 
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this problem, more liberal criterion for inclusion of predictors following univariate 
analysis (p < .15 or .20) is advised.  Only four of the multivariate studies in this review 
specifically identified variable selection criteria with a univariate significance level 
greater than p < .05 (Komatsu et al., 2003; Kyne, Sougioultzis, McFarland, & Kelly, 
2002; Muto et al., 2005; Pulvirenti et al., 2002).  The remainder of the studies eliminated 
variables that might have had an independent association with the development of CDAD 
following multivariate testing, and indeed limited inclusion of variables that may have 
clinical relevance.  Stepwise procedures hold the allure of statistical criteria for decisions 
about inclusion of predictors, rather than the tedium of formulating specific hypotheses 
about the role of multiple variables in association with CDAD.  However, such a strategy 
limits the applicability of the predictive model to clinical practice. 
A limitation common to most of the studies within this review is the lack of a 
consistent case definition for CDAD among studies.   Clinically, both the presentation of 
diarrhea and confirmatory laboratory stool testing or endoscopic examination are 
considered essential for a diagnosis of CDAD.  Although 73% of the studies include 
some type of change in bowel function as a part of the case definition, the definition of 
diarrhea varied greatly between studies.  This problem of defining diarrhea and its impact 
on the interpretation of diarrhea study findings has been previously discussed (Bliss, 
Guenter, & Settel, 1992; Steele, 2006).  Diarrhea defined by the number of bowel 
movements, consistency of stool, and duration of the symptom varies among studies, 
making meta-analysis unrealistic.  Reliable instruments exist for classification of stool 
characteristics (Bliss, Larson, Burr, & Savik, 2001; Whelan, Judd, & Taylor, 2004).  
However, their use in retrospective designs that rely upon medical record documentation 
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is impractical.  More than half of the studies in this sample were of a retrospective cohort 
or case-control design.  Confirmatory testing was part of the case definition for 83% of 
the original studies.  However, a variety of testing methods were used, making meta-
analysis, as advocated by Bignardi, questionable.  Two studies assigned subjects to case 
status based only on the diagnosis recorded in the medical record by a clinician (Buchner 
& Sonnenberg, 2001; Harbarth, Samore, & Carmeli, 2001) and a third publication, a 
letter to the editor reporting research findings,  did not include details regarding case 
definition (Iizuka et al., 2004).   
A large portion of the studies relied upon laboratory records of diagnostic stool 
testing for the selection of subjects and cases.  This strategy assumes that all specimens 
submitted for C. difficile testing are from symptomatic individuals, and that all persons 
without stool testing are both asymptomatic and would produce negative stool testing 
results.  Thus, a type of diagnostic bias was inherent in the design of these studies. 
Comparison of studies is also complicated by the variety of ways in which 
specific risk factor exposure was measured.  This is especially evident in assessing 
antibiotic exposure and severity of illness.  Antibiotic exposure was measured by number 
of drugs, number of doses, number of days on a specific agent, appropriate versus 
inappropriate use, specific drug regimen, and by a simple binary measure of exposure.  
Only one study (Al-Eidan, :McElnay, Scott, & Kearney, 2000) attempted to use a 
standardized measure of antibiotic exposure, the Defined Daily Doses established by the 
World Health Organization  for drug utilization research.   
Similarly, the concept of severity of illness responsible for hospitalization was 
measured in a number of ways.  The number of medical or surgical procedures, number 
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of organ systems affected, critical care or ventilator use, prolonged hospital stay and 
disease staging were all forms of severity assessment.  Only two instruments were used 
for categorization of this variable in a consistent manner.  The Horn’s Severity of Illness 
index was used in three studies (Kyne, Sougioultzis, McFarland, & Kelly, 2002; 
L.McFarland, 1995; Vesta, Wells, Gentry, & Stipek, 2005), while the Charlson Index of 
Comorbidity was used in two investigations (Dial, Alrasadi, Manoukian, Huang, & 
Menzies, 2004; Loo et al., 2005).  Only Kyne et al. addressed the sensitivity, specificity, 
and predictive value of the tool in discussion of the findings.   
External validity 
Subjects chosen for the studies within this review were described as 
representative of the target population in 40 (66%) publications.  Twenty studies (33%) 
described inclusion criteria for study eligibility and an additional 20 described both 
inclusion and exclusion criteria for participation.  For this reason, generalization of study 
findings to a specific target population is rather limited. 
Funding disclosure 
Only 13 (21%) publications acknowledged a funding source or study sponsorship 
either within the body of the paper or the notes and acknowledgements.  This may due to 
lack of sponsorship, journal standards and restrictions regarding acknowledgements, or 
simply reflective of the period of time in which the studies were published.  In the 
checklist proposed by Downs and Black (1998), there is no question regarding 
sponsorship.  However in the 2002 report by West et al. for the Agency for Healthcare 
Research and Quality, sponsorship is considered an essential criterion for evaluating 
quality.  Of the 42 studies published before 2003, only 14% include funding information, 
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but 37% of those published in 2003 or later include this information.  It is anticipated that 
this percent will increase over time as qualitative assessment of research findings 
becomes more refined. 
Quantitative Assessment of Research Findings 
In order to evaluate the strength of the association between specific ecological 
variables and the development of CDAD, published odds ratio (O.R.) and relative risk 
(R.R.) data were systematically examined similar to the method used in the qualitative 
portion of the meta-analysis publication (Bignardi, 1998).  When O.R. or R.R. data was 
not provided, it was calculated, if possible, from data within the published article.  
Evidence supportive of the association of a risk factor with the development of CDAD 
was defined either of the following:  (1) a statistically significant (p<0.05) positive 
univariate O.R. or R.R. in the majority of studies using univariate analysis to evaluate the 
risk factor or (2) a statistically significant (p<0.05), positive multivariate O.R.  Evidence 
was considered non-supportive of an association if it failed to meet either of the above 
criteria or if two or more studies using multivariate analysis failed to identify a 
statistically significant positive association for the risk factor. 
Age 
The effect of age upon the development of CDAD in hospitalized populations is 
uncertain.  Within this body of literature, age has been studied as a confounder, a risk 
factor, and an effect modifier.  Age is often considered a confounding variable in 
epidemiological investigations.  Eight studies used matching to control for potential 
confounding effects of age, thus eliminating it for consideration as a risk factor for the 
development of CDAD (Bliss et al., 1998; Changela et al., 2004; Cunningham, Dale, 
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Undy, & Gaunt, 2003; Kreisel, Thomas, Silver, & Cunningham, 1995; Loo et al., 2005; 
MacGowan et al., 1997; Thamlikitkul, Danpakdi, & Chokloikaew, 1996; Vesta, Wells, 
Gentry, & Stipek, 2005; Yip, Loeb, Salama, Moss, & Olde, 2001).  An additional study 
did not use matching for age, but selected controls within the same age-range as case 
patients, thereby minimizing the possibility of differences in age between cases and 
controls (Changela et al., 2004).   
Twenty-eight publications included age as a variable in the statistical analysis of 
study findings.  Eight publications reported statistically significant differences in mean 
age between CDAD subjects and non-CDAD comparison subjects within the presentation 
of demographic data (Ackermann et al., 2005; Barbut et al., 2005; Buchner & 
Sonnenberg, 2002; Climo et al., 1998; Harbarth, Samore, & Carmeli, 2001; Kent, Rubin, 
Wroblewski, Hanff, & Silen, 1998; McFarland, 1995; Svenungsson, Lagergren, & 
Lundberg, 2001).   
Age was evaluated as a specific risk factor for CDAD in 13 studies.  Of the five 
studies reporting only univariate analysis, four reported statistically significant positive 
associations with CDAD (Ackermann et al., 2005; Karlstrom, Fryklund, Tullus, Burman, 
& Group, 1998; Kyne, Sougioultzis, McFarland, & Kelly, 2002; Watanakunakorn, 
Watanakunakorn, & Hazy, 1996).  Increasing age was found to have a statistically 
significant positive association in five additional studies using multivariate data analysis 
(Andrews, Raboud, Kassen, & Enns, 2003; Chang & Nelson, 2000; Modena, Bearelly, 
Swartz, & Friedenberg, 2005; Muto et al., 2005; Starr, Martin, McCoubrey, Gibson, & 
Poxton, 2003).  Although Harbarth et al. (2001) reported a univariate O.R. of 2.5 with a 
significance level sufficient for entry into multivariate analysis (p = .08), age was not 
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entered as a variable in the logistic regression analysis. Only one publication within this 
review reported a non-significant association (Kyne et al., 1999).  Therefore, the findings 
of this review are consistent with those of Bignardi (1998) who reported substantial 
evidence for increasing age as a risk factor for CDAD.  
A problem noted in comparing research findings regarding this variable is the 
disparity in ages considered reflective of advanced age.  While some investigations 
considered subjects 60 years and older to be geriatric, others used 70 or 75 years as a cut-
point.  None of the published studies included information about why a particular age 
range was selected as a risk factor for data collection and analysis.   
It is likely that age is also an effect modifier for development of CDAD.  As age 
increases, the likelihood of exposure to toxigenic strains of the organism increases, 
principally through institutionalization in a hospital, rehabilitation, or long-term care 
setting.  Institutionalization will not be investigated as a potential risk factor for CDAD in 
the present study because all subjects will be inpatients within an acute care hospital.  
Several investigations within this review reported significant differences in CDAD rates 
for nursing home versus community-dwelling adults (Al-Eidan, :McElnay, Scott, & 
Kearney, 2000; Cooper, Lederman, & Salata, 1995; Kent, Rubin, Wroblewski, Hanff, & 
Silen, 1998) .  A descriptive study demonstrating a reduction in CDAD within geriatric 
wards of several acute care hospitals following implementation of an enhanced infection 
control program suggests that infection exposure may play a larger role than age in 
disease development (Stone, Beric, Quick, Balestrini, & Kibbler, 1998).  Treatment of 
chronic illnesses is more common in old age, and acute exacerbations and complications 
increase the likelihood of multiple drug exposures, including antibiotics.  A significant 
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difference has been demonstrated in the mean age of subjects exposed to antibiotics prior 
to the development of CDAD and those with no previous antibiotic exposure 
(Svenungsson, Lagergren, & Lundberg, 2001).  Aging also makes an individual more 
likely to be exposed to tube feeding as a substitute or supplement to oral feeding.  This 
type of artificial nutrition is associated with major changes in fecal flora (Schneider et al., 
2000) and has been identified as a significant risk factor for both acquisition of the 
organism and development of CDAD (Bliss et al., 1998; Komatsu et al., 2003).   
Acid Suppression 
The administration of drugs to suppress or neutralize gastric acid production has 
been explored as a biologically plausible risk factor for the development of CDAD.  
Bignardi (1998) found substantial evidence for use of “anti-ulcer medication including 
antacids and H2 blockers” (p.5).  A total of 16 studies were identified which considered 
alteration of gastric acid as a risk factor.  However, within this review, acid suppressive 
medications were examined in three separate categories: antacids, histamine-2 blocking 
agents (H2), and proton pump inhibitors (PPI), as each class of drugs has a distinctly 
different physiologic mechanism of action. 
Antacid medications were studied in six publications.  Two were analyzed using 
univariate techniques only, while four described multivariate data analysis.  Non-
significant findings were reported for five studies (Aziz, Ayis, Gould, & Rawlins, 2001; 
Barbut et al., 1997; Hornbuckle et al., 1998; Kyne et al., 1999; Watanakunakorn, 
Watanakunakorn, & Hazy, 1996).  Only one of these publications reported statistically 
significant positive associations for antacid medication use (Tacconelli et al., 1998).   
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Of the nine studies measuring exposure to H2 blocking agents, three reported 
non-significant univariate test results (Dial, Alrasadi, Manoukian, Huang, & Menzies, 
2004; Loo et al., 2005; Watanakunakorn, Watanakunakorn, & Hazy, 1996) and another 
reported non-significant multivariate results (Kyne et al., 1999).  A high-magnitude 
statistically significant positive association was identified in one univariate study (Yip, 
Loeb, Salama, Moss, & Olde, 2001) and a more moderate significant multivariate 
association was reported by Muto (2005).   
The use of proton pump inhibitor (PPI) agents has generated the most consistent 
associations for acid suppressive exposure across studies.  Ten publications in this review 
assessed the relationship between PPI drugs and CDAD.  Three univariate analyses 
produced statistically significant positive associations (Al-Tureihi, Hassoun, Wolf-Klein, 
& Isenberg, 2005; Cunningham, Dale, Undy, & Gaunt, 2003; Yearsley et al., 2006), but 
Kyne (1999) and Loo (2005) both reported non-significance.  Two reports indicated 
statistically significant multivariate O.R. for PPI exposure (Dial, Alrasadi, Manoukian, 
Huang, & Menzies, 2004; Muto et al., 2005).   
All of the studies investigating acid suppression as a risk factor for CDAD 
measured exposure dichotomously; therefore, a dose response could not be assessed from 
this review.  No evidence was found to suggest that antacids, which neutralize the pH 
level of gastric secretions, are associated with the development of CDAD.  However, H2 
blockers and PPI agents, which exert an effect at the cellular level and result in a decrease 
in acid production, have some evidence to suggest their influence.  Future research 
should consider these as separate drug categories for data collection, and an attempt 
should be made to determine if there is a dose-response for either type of agent. 
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Antibiotic Administration 
The risk factor for CDAD development investigated the most extensively over the 
past thirty years is antibiotic exposure.  The scientific literature includes studies of both 
the amount of antibiotic exposure associated with CDAD and the specific antibiotics 
most likely to be associated with the disease.  Although one meta-analysis reported a 
significant association between antibiotic exposure and CDAD (Bignardi, 1998),  a 
systematic review of published epidemiologic studies between 1978 and 2001 identified 
threats to internal validity in a majority of the studies due to incorrect control group 
selection, inadequate sample sizes, inadequate control of confounders, and 
misclassification bias in case identification (Thomas, Stevenson, & Riley, 2003).   
The original literature search identified 66 publications in which antibiotic 
exposure was considered as a risk factor for the development of CDAD.  In addition to a 
meta-analysis and structured review, there were 64 original research publications 
identified.  Of these studies, seven were descriptive and provided no information about 
the disease frequency, the role of chance, or the strength of the association (Bulstrode et 
al., 1997; Crabtree, Pellitier, Gleason, Pruett, & Sawyer, 1999; Gorecki, Schein, 
Rucinski, & Wise, 1999; Impallomeni, Galletly, Wort, Staff, & Rogers, 1995; Khan & 
Cheesbrough, 2003; Shek, Stacey, Rendell, Hellier, & Hanson, 2000; Stone, Beric, 
Quick, Balestrini, & Kibbler, 1998).   
A major difficulty in assessing the strength of evidence regarding antibiotic 
exposure as a CDAD risk factor is the multiple ways in which exposure has been 
operationalized and measured.  More than 25% of the studies measured antibiotic 
exposure via more than one method.  The most frequently described measure, reported in 
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41 papers, and was a simple binary assessment of exposure to a specific antibiotic drug 
classification.  Twenty-two papers measured any antibiotic exposure, while 12 measured 
the number of different drug agents used.  Three studies examined specific antibiotic 
regimens and two classified antibiotic use as “appropriate” or “inappropriate”.  
Surprisingly, only four of the publications attempted to quantify antibiotic exposure by 
measuring the number of doses, and only one did so through the use of a standardized 
dose measure.  A unit of measure, the defined daily dose (DDD), represents the average 
daily adult dose for a drug when used for its primary indication (Pelle, Gilchrist, Lawson, 
Jacklin, & Franklin, 2006).  This measure has been advocated for drug exposure research 
by the World Health Organization to facilitate comparisons of drug usage despite 
international variations in clinical practice patterns.  Only one of the studies included in 
this review used the DDD unit for measuring antibiotic exposure, although the system has 
been in effect for over 20 years (Al-eidan).   
In considering all antibiotic exposure as a whole, study results present conflicting 
evidence.  Bignardi (1998) reported a pooled O.R. of 5.9 for a binary measure of 
antibiotic exposure.  One multivariate study published after 1998 (Cunningham, Dale, 
Undy, & Gaunt, 2003) and five univariate studies reported statistically significant 
positive associations for antibiotic exposure (Blot et al., 2003; Loo et al., 2005; Starr, 
Martin, McCoubrey, Gibson, & Poxton, 2003; Svenungsson, Lagergren, & Lundberg, 
2001; Yearsley et al., 2006).  This provides strong evidence for antibiotic exposure as a 
consistent and independent risk factor for CDAD acquisition. 
In contrast, four studies published after the Bignardi paper reported non-
significant multivariate O.R. for this same variable (Chang & Nelson, 2000; Harbarth, 
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Samore, & Carmeli, 2001; Loo et al., 2005; McCusker, Harris, Perencevich, & 
Roghmann, 2003).  Two case-control (Komatsu et al., 2003; Vesta, Wells, Gentry, & 
Stipek, 2005) and two prospective cohort  studies (Cleary et al., 1998; Kyne, 
Sougioultzis, McFarland, & Kelly, 2002) did not enter antibiotic exposure into 
multivariate analysis based upon overly stringent bivariate test results.  Barbut et al. 
(2005) did not include antibiotic exposure in the multivariate analysis due to both low 
magnitude and non-significance on univariate testing.  In a sample of oncology patients, 
antibiotic exposure was associated with CDAD only in patients also receiving 
chemotherapy (Blot et al., 2003).  Both treatment with any antibiotic and treatment with 
specific classes of antibiotics were entered into logistic regression models in a 
prospective cohort study, and both failed to demonstrate statistical significance (Bliss et 
al., 1998).  This discrepancy in findings indicates the need for a more accurate and 
quantitative means of measuring antibiotic exposure in future research. 
A number of studies did attempt to operationalize the burden of antibiotic 
exposure through measurement of the number of different antibiotic agents to which 
subjects were exposed.  Three studies reported statistically significant differences 
between cases and comparison subjects in the mean number of antibiotic agents used, but 
these studies did not report measures of association or provide sufficient information 
within the publication to calculate these measures (Climo et al., 1998; Kyne, 
Sougioultzis, McFarland, & Kelly, 2002; Loo et al., 2005).  Pulvirenti et al. (2002A) 
reported a statistically significant, positive multivariate O.R. for the number of 
antibiotics.  Dial et al. (2004) also reported a statistically significant, positive multivariate 
O.R.s for the number of antibiotics in a cohort study, but a case-control study reported in 
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the same paper did not have statistically significant findings.   Statistically significant 
positive univariate associations were reported by five other studies (Andrews, Raboud, 
Kassen, & Enns, 2003; Harbarth, Samore, & Carmeli, 2001; Lai, Melvin, Menard, 
Kotilainen, & Baker, 1997; L. V. McFarland, 1995; J.J. Pulvirenti et al., 2002). 
Assessment of antibiotic burden measured based on a simple count of the number 
of doses has not yielded clinically important information.  No significant difference was 
found in the mean number of antibiotic doses received between cases and comparison 
subjects in one investigation (MacGowan et al., 1997), and Kyne et al. (1999) reported a 
positive, but not statistically significant multivariate O.R. for the number of antibiotic 
doses.  It would appear that a count of doses administered is not useful in quantifying 
antibiotic burden.  Al-Eidan et al. (2000) attempted to quantify doses using the Defined 
Daily Dose system.  However, the number of doses used for each drug were calculated 
based upon Pharmacy purchasing data, and were not obtained from individual patient 
records.  Therefore the actual degree of antibiotic exposure for individual subjects was 
not accurately measured. 
Within this review, researchers identified a number of antimicrobial drug 
categories as exposures associated with CDAD. These findings are summarized in Table 
3.  Antibiotic agents are grouped by their pharmacologic drug category in column 1.  
Studies reporting non-significant associations are listed in column 2, those reporting 
statistically significant univariate associations are listed in column 3, and studies 
reporting statistically significant multivariate associations are listed in column 4. 
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Table 3 
Reported Significance of Test Results for Antibiotic Exposure by Drug Category 
 Significance of the Association with CDAD 
 
Drug Category Non-significant  + Univariate  + Multivariate  
 
Aminioglycosides Johnson et al., 1999;  
Komatsu et al., 2003 
Muto et al., 2005 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Shah, Lewis, Leopold, 
Dunstan, & Woodhouse 
Vesta, Wells, Gentry, & 
Stipek, 2005 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
Yip, Loeb, Salama, Moss, 
& Olde, 2001 
 
Barbut et al., 1997 
Bliss et al., 1998 
Changela et al., 2004  
Cooper, Lederman, & 
Salata, 1995 
Halim, Peterson, Friesen, 
& Ott, 1997 
Harbarth, Samore, & 
Carmeli, 2001 
Kyne, 2002 Schwaber et 
al., 2000* 
Talon et al., 1995 
 
Loo et al., 2005* 
 
 
Penecillins Aziz, Gould, & Rawlins, 
2001 
Harbarth, Samore, & 
Carmeli, 2001 
Johnson 
Komatsu et al., 2003 
Kyneet al., 1998 
Kyne et al., 1999 
Loo et al., 2005 
McCusker, Harris, 
Perencevich, & 
Roghmann, 2003 
Mody, Smith, & dever, 
2001 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Shah, Lewis, Leopold, 
Dunstan, &  Woodhouse 
Vesta, Wells, Gentry, & 
Stipek, 2005 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
Yip, Loeb, Salama, Moss, 
& Olde, 2001 
Al-Eidan, McElnay, Scott, 
& Kearney, 2000 et al., 
2000 Changela 
Cooper, Lederman, & 
Salata, 1995 
Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 
Rao, Rao, & Starke, 2003 
Schwaber et al., 2000 
Starr, Martin, 
McCoubrey, Gibson, & 
Poxton, 2003 
Talon et al., 1995 
 
Barbut et al, 1997 
Talon et al., 1995 
Cephalosporins Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004  
Johnson et al., 1999 
Komatsu et al., 2003 
Kyne et al., 199 
Al-Eidan, McElnay, Scott, 
& Kearney, 2000;  
Arrango et al., 2006 
Barbut et al., 1997 
Changela et al., 2004 
Cooper, Lederman, &  
Aziz, Gould, & Rawlins, 
2001 
Bliss et al., 1998 
Loo et al., 2005 
Yip, Loeb, Salama, 
Moss, & Olde, 2001 
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Table 3 (Continued) 
 Significance of the Association with CDAD 
 
Drug Category Non-significant  + Univariate  + Multivariate  
 
Cephalosporins - 
continued 
McCusker, Harris, 
Perencevich, & 
Roghmann, 2003 
Mody, Smith, & dever, 
2001 (1st generation) 
Muto et al., 2005 (1st and 
2nd generation) 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Vesta, Wells, Gentry, & 
Stipek, 2005 
 
Salata, 1995 
Halim, Peterson, Friesen, 
& Ott, 1997 
Harbarth, Samore, & 
Carmeli, 2001 
Kyne et al., 1998 
Mody, Smith, & dever, 
2001 (3rd generation) 
Muto et al., 2005 (3rd and 
4th generation) 
Rao, Rao, & Starke, 2003 
Schwaber et al., 2000 
Settle, Wilcox, Fawley, 
Corrado, & Hawkey, 1998 
Shah, Lewis, Leopold, 
Dunstan, & Woodhouse 
Starr, Martin, 
McCoubrey, Gibson, & 
Poxton, 2003 
Talon et al., 1995’ 
Tumbarello, Tacconelli, 
Leone, Cauda, & Ortona, 
1995 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
 
Quinolones Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 (case 
control) 
Komatsu et al., 2003 
Kyne et al, 1998 
Kyne, Sougioultzis, 
McFarland, & Kelly, 2002 
Mody, Smith, & dever, 
2001 
Muto et al., 2005 
(ciprofloxacin) 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Rao, Rao, & Starke, 2003 
Shah, Lewis, Leopold, 
Dunstan, & Woodhouse 
Talon et al., 1995 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
 
Barbut et al., 1997* 
Bilgrami et al., 1999* 
Changela 
Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 (cohort) 
Harbarth, Samore, & 
Carmeli, 2001 
Muto et al., 2005 
(levofloxacin) 
Pulvirenti, 2002A 
Schwaber et al., 2000 
 
Loo et al., 2005 
McCusker, Harris, 
Perencevich, & 
Roghmann, 2003 
Yip, Loeb, Salama, 
Moss, & Olde, 2001 
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Table 3 (Continued) 
 Significance of the Association with CDAD 
 
Drug Category Non-significant  + Univariate  + Multivariate  
 
Macrolides Harbarth, Samore, & 
Carmeli, 2001 
Komatsu et al., 2003 
Kyne, 1998 
Loo et al., 2005 
Mody, Smith, & dever, 
2001 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Shah, Lewis, Leopold, 
Dunstan, & Woodhouse 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
 
Changela et al., 2004 
Muto et al., 2005 
Pulvirenti et al., 2002A 
Schwaber et al., 2000 
 
Clindamycin Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 (case-
control study) 
Komatsu et al., 2003 
Kyne et al., 1998 
Kyne, Sougioultzis, 
McFarland, & Kelly, 2002 
McCusker, Harris, 
Perencevich, & 
Roghmann, 2003 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
Yip, Loeb, Salama, Moss, 
& Olde, 2001 
Changela 
Harbarth, Samore, & 
Carmeli, 2001 
Johnson 
Mody, Smith, & dever, 
2001 
Muto et al., 2005 
Rao, Rao, & Starke, 2003 
Schwaber et al., 2000 
Thamliktkul, Danpakdi, & 
Chokloikaew, 1996 
Tumbarello, Tacconelli, 
Leone, Cauda, & Ortona, 
1995 
Barbut, 1997 
Chang & Nelson, 2000 
Loo et al., 2005 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Sulfonamides Aziz, Gould, & Rawlins, 
2001 
Harbarth, Samore, & 
Carmeli, 2001 
Kyne, 2002 
Shah, Lewis, Leopold, 
Dunstan, & Woodhouse 
Yip, Loeb, Salama, Moss, 
& Olde, 2001 
Barbut et al., 1997* 
Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 
Muto et al., 2005 
Schwaber et al., 2000* 
Tumbarello, Tacconelli, 
Leone, Cauda, & Ortona, 
1995 
 
Tetracyclines Changela et al., 2004 
Kyne, Sougioultzis, 
McFarland, & Kelly, 2002 
Muto et al., 2005 
  
Carbapenems 
 
Komatsu et al., 2003 
Loo et al., 2005 
Muto et al., 2005 
 
Changela et al., 2004 
Harbarth, Samore, & 
Carmeli, 2001 
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Table 3 (Continued) 
 Significance of the Association with CDAD 
 
Drug Category Non-significant  + Univariate  + Multivariate  
 
Glycopeptides Johnson et al., 1999 
Komatsu et al., 2003 
Loo et al., 2005  
Mody, Smith, & dever, 
2001 
Muto et al., 2005 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Shah, Lewis, Leopold, 
Dunstan, & Woodhouse 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
 
Arrango et al., 2006 
Barbutet al., 1997 
Changela et al., 2004 
Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 
Schwaber et al., 2000 
 
Metronidazole Kyne, Sougioultzis, 
McFarland, & Kelly, 2002 
Mody, Smith, & dever, 
2001 
Palmore, Sohn, Malak, 
Eagan, & Sepkowitz, 
2005 
Watanakunakorn, 
Watanakunakorn, & 
Hazy, 1996 
Wren, Ahmed, Jamal, & 
Safadi, 2005 
Barbut et al., 1997* 
Chakrabarti, Lees, Jones, 
& Milligan, 2000 
Dial, Alrasadi, 
Manoukian, Huang, & 
Menzies, 2004 
Pulvirenti et al., 2002A 
Pulvirenti et al., 2002B 
Schwaber et al., 2000 
 
Statistically significant positive O.R. with magnitude > 1.0 
 
Within the penicillin class, results were very varied.  Two studies demonstrated 
independence for penicillin exposure, and seven demonstrated consistency.  The overall 
number of studies with non-significant findings, however, outnumbers those with 
significant findings.  The penicillin class of drugs is one in which successive generations 
have been developed in an attempt to avoid drug resistance.  For this reason, a simple 
grouping of all penicillin’s may not be adequate for epidemiological purposes.  Future 
research regarding drug classes and exposure should distinguish these groupings in 
addition to determining if there is a dose-response to sub-group penicillin. 
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Cephalosporin antibiotics were investigated in the largest number of studies.  Four 
reported independent associations after multivariate analysis, and 17 reported significant 
univariate findings, considerably more than the nine that reported non-significant 
findings.  There is strong evidence to support cephalosporin drug exposure as a risk 
factor for CDAD. 
Within the quinolone class of antibiotics, there were three studies reporting 
independent association with quinolone exposure after multivariate analysis to control for 
confounders.  There were also seven univariate studies with statistically significant 
results.  However, the author also reviewed 12 studies that reported negative findings for 
quinolone as a risk factor.   Future research needs to examine this exposure more fully.  
The quinolones represent a clinically important category of antibiotic, and their use as a 
risk factor has been investigated in several hospital outbreaks. 
Macrolide antibiotics did not have sufficient evidence in this review to consider 
them a substantial risk factor in the development of CDAD.  There were no studies that 
met the criterion of independence, and only four that met the criterion of consistency.  
There were seven studies that reported non-significant results for this risk factor. 
Not surprisingly, evidence continues to support clindamycin as a risk factor for 
CDAD.  Although there were seven studies reporting non-significant results for 
clindamycin exposure within this body of literature, these studies were overshadowed by 
those with significant findings.  Four studies reported significant multivariate results and 
nine reported significant univariate results for clindamycin exposure. 
The category of carbapenems had no reports with multivariate support, and an 
even number of reports with significant and non-significant findings.  There is not 
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sufficient evidence at this time to consider the carbapenems a serious risk factor for the 
development of CDAD.   
Less than half of the studies that investigated glycopeptide antibiotic use as a risk 
factor reported statistically significant univariate measures of association, and there were 
no studies with significant multivariate findings.  This is not surprising, since 
vancomycin, a major glycopeptide used to treat recurrent or resistant CDAD is in this 
category of drug.  However, the assessment of evidence regarding metronidazole was 
unexpected.  Metronidazole is considered by many clinicians to be the first line drug used 
to treat CDAD cases that fail to respond to withdrawal of antibiotic therapy.  Studies with 
significant and non-significant measures of association for metronidazole use were 
almost equally divided. 
The most difficult aspect of evaluating the association of CDAD with antibiotic 
exposure is the difficulty in establishing a dose response.  Inconsistent methods of 
measuring antibiotic exposure complicate comparisons between studies.  Median number 
of doses given to a specific subject, daily average antibiotic doses dispensed by an 
institutional pharmacy, and simple frequency counts of the number of subjects receiving 
a particular antibiotic agent have all been used to measure antibiotic exposure.  Although 
biologic markers, such as serum drug levels, are not available for all antimicrobial drugs, 
even when such testing is available, it is not included in published descriptions of 
antibiotic exposure, and is not possible in any type of retrospective study.  
35 
Diet 
Tube feeding has been investigated as a risk factor for the development of CDAD, 
as has malnutrition and hypoalbuminemia.  Within this review, 12 studies were located 
that examined tube feeding and six considering nutritional deficits as a risk factor.   
Tube Feeding.  Twelve analytical epidemiology studies were located that 
considered tube feeding via either nasogastric or percutaneous abdominal routes as a 
potential risk factor for the acquisition of CDAD.  A letter to the editor describing data 
supporting elemental diets as a risk factor for CDAD was excluded due to lack of details 
(Iizuka et al., 2004).   
Of the two studies which analyzed data using only univariate analysis, one 
reported data sufficient to calculate an O.R. of 2.38 (p<0.05) (Halim, Peterson, Friesen, & 
Ott, 1997), and the other reported a non-significant positive association 
(Watanakunakorn, Watanakunakorn, & Hazy, 1996).  Therefore, satisfaction of the 
consistency criterion was unclear. 
Ten studies used multivariate data analysis methods.  Of these studies, three 
evaluated enteral feeding as a variable and determined that it was sufficiently related to 
other variables to eliminate for consideration as an independent risk factor (Kyne, 
Sougioultzis, McFarland, & Kelly, 2002; Loo et al., 2005; Shah, Lewis, Leopold, 
Dunstan, & Woodhouse, 2000).  Two studies reported non-significant O.R. (Kent, Rubin, 
Wroblewski, Hanff, & Silen, 1998; Yip, Loeb, Salama, Moss, & Olde, 2001), although 
the specific values were not published.  Four studies found enteral feeding to be an 
independent risk factor for CDAD (D. Bliss, Guenter, & Settel, 1992; Buchner & 
Sonnenberg, 2001; Komatsu et al., 2003; Talon et al., 1995), and a fifth found enteral 
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feeding by nasogastric tube, but not via percutaneously inserted gastrostomy tube (Kyne 
et al., 1999) to be independently associated with the disease.  Lai reported a statistically 
significant negative association between the presence of a nasogastric tube and CDAD. 
Enteral feeding appears to be a substantial risk factor for CDAD.  However, since this 
mode of feeding cannot exist without the presence of the administration tube, the 
possibility that enteral feeding is a confounder, rather than a risk factor, should be 
considered.  Bignardi (1998) identified “nasogastric tubes” as a substantial risk factor, but 
did not address enteral feeding.  An alternative explanation for the apparent association 
between enteral feeding and CDAD has been proposed as “feeding tubes are frequently 
given to immune compromised patients with dietary deficiencies and multiple other 
comorbid conditions who have spent appreciable amount of time in the hospital.  Most 
importantly, all percutaneous tubes are inserted under antibiotic 
prophylaxis”(Sonnenberg, 2005).  
Malnutrition.  Of the studies that examined nutritional deficits in association with 
CDAD, four used univariate analysis methods only.  Of these studies, three reported 
statistically significant positive associations between CDAD and malnutrition (Al-
Tureihi, Hassoun, Wolf-Klein, & Isenberg, 2005; Andrews, Raboud, Kassen, & Enns, 
2003; Rubin, Bodenstein, & Kent, 1995) as measured by serum hypoalbuminemia.  The 
other report measured malnutrition via the Prognostic Nutritional Index, a calculation 
based on a number of laboratory and clinical factors (Dansinger et al., 1996) and 
identified an association between protein-losing enteropathy and CDAD.   
 Four studies also reported multivariate testing, however the Modena et al. and 
Andrews et al. studies omitted entry of the nutritional variable into multivariate analysis 
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due to excess missing data points.  Buchner and Sonnenberg reported a statistically 
significant O.R. of 2.01 for the variable of malnutrition as an independent predictor of 
CDAD, but Shah did not report the multivariate O.R., indicating that it was no longer 
statistically significant.   
The loss of serum protein identified by Dansinger et al. raises important questions 
about the relationship between malnutrition, susceptibility to infection, and diarrhea.  
This variable should be considered a substantial risk factor for inclusion in future 
research.  
Cathartic Administration 
The impact of laxatives and bowel preparation regimens upon development of 
CDAD has not been extensively studies.  Among the publications reviewed, six included 
data regarding laxative use and one regarding bowel preparation regimens.   
A statistically significant R.R. of 3.2 was reported in association with mechanical 
bowel preparation among a cohort of surgical patients (McCarter, Abularrage, Velasco, 
Davis, & Daly, 1996),  This risk factor was not included in the Bignardi list, but most 
likely warrants inclusion in future studies. 
Six studies investigated laxative use in association with the development of 
CDAD.  Watanakunakorn et al. (1996) reported a non-significant negative association in 
a study of a general hospital population.  However, an investigation of CDAD generated 
from an HIV-infected population identified a statistically significant positive association 
(Pulverenti et al., 2002).  Four publications included laxative use in multivariate studies.  
Barbut et al. found a negative association between CDAD and laxative use on univariate 
testing, but did not include the variable in multivariate analysis, although the p value of 
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0.20 would have been sufficient for inclusion in a conditional logistic regression analysis.  
Kent et al. (1998) also reported a non-significant p value, and therefore did not include 
laxative use in the regression analysis.  Kyne et al. (1999) reported a non-significant 
negative association.  Only one paper reported statistical significance after multivariate 
analysis, but it was a negative association for both the general drug category of 
“laxatives” as well as the specific agent lactulose (Shah, Lewis, Leopold, Dunstan, & 
Woodhouse, 2000).   
Laxative use does not appear to increase the risk of CDAD.  It is possible that 
laxative use may exert a protective effect upon the bowel by facilitating the elimination 
of potentially toxigenic organisms.  It may, however, serve as a confounder in studies in 
which subjects are selected based upon hospitalized persons who have stools submitted 
for laboratory testing due to loose or diarrheal stools.  Bowel preparation is associated 
with CDAD in surgical patients, but this needs more study to determine if the association 
is consistent across more populations. 
Severity of Illness 
The immune response to infectious agent exposure can be impaired by a variety 
of mechanisms, including disease and injury.  A number of investigations have explored 
the concept of severity of illness in association with the development of CDAD.  A total 
of 22 studies were included in the review that explored the association between 
concomitant illness or injury and CDAD.  The concept was operationalized in a variety of 
ways, including comorbidity, stage of illness, hospital length of stay, intensive care unit 
stay, and a severity of illness index (Horn & Horn, 1986).   
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The most frequently used method used to measure severity of illness within this 
group of studies was comorbidity.  Five studies considered the presence or absence of 
specific diseases as a measure of comorbidity.  Significant positive univariate 
associations were reported for chronic renal failure (Cunney, Magee, McNamara, Smyth, 
& Walshe, 1998; Harbarth, Samore, & Carmeli, 2001) and renal insufficiency (Rubin, 
Bodenstein, & Kent, 1995). Although Yip et al. (2001) reported a non-significant 
univariate O.R. for renal failure, the magnitude association was 7.0.  Dial et al. also 
reported a significant positive multivariate O.R. of 4.3 for chronic renal failure.  Other 
statistically significant positive univariate associations have been reported for 
gastrointestinal illness and anemia (Harbarth, Samore, & Carmeli, 2001), chronic 
obstructive pulmonary disease (Rubin, Bodenstein, & Kent, 1995) and malignancy 
(Rubin, Bodenstein, & Kent, 1995; Yip, Loeb, Salama, Moss, & Olde, 2001).   
Andrews et al. (2003) reported a significant positive multivariate O.R. for 
increasing number of organ systems affected by comorbid illness.  Two reports indicated 
a statistically significant difference in the number of diagnoses between CDAD cases and 
controls (Buchner & Sonnenberg, 2001; Mody, Smith, & Dever, 2001), but measures of 
association were not reported.  Likewise, Buchner and Sonnenberg reported statistically 
significant differences in the number of medical and surgical procedures performed on 
cases versus controls.   
A problem common to all of these studies is the fact that there between subjects, 
there may be a great deal of variation in the impact in which a medical diagnosis makes 
on the overall health of the individual.  Therefore, a diagnosis category, or a count of 
diagnoses, is not a valid measure of comorbidity.  When a standardized measure, the 
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Charlson Index of comorbidity, was used to assess differences between CDAD cases and 
a comparison group, no significant differences were found (Loo et al., 2005). 
The stage of illness for Human Immunodeficiency Virus (HIV)-infected adults 
was examined in two separate studies.  Although Pulverenti et al. (2005) found positive 
associations through progressive stages of HIV infection, these associations were not 
statistically significant on univariate analysis.  However, low CD4 cell count has been 
significantly associated with CDAD in univariate analysis (Tacconelli et al., 1998), and 
both a history of opportunistic infection (Pulverenti et al., 2005) and a CD4 count below 
50 mm3 (Barbut et al., 1997) have been reported to have statistically significant positive 
associations following multivariate analysis.  These findings provide biologically 
plausible support for immunosuppression, manifested by both opportunistic infection and 
a decline in CD4, as a  factor in the causation of CDAD. 
The length of hospitalization is significantly longer for persons who develop 
CDAD (Buchner & Sonnenberg, 2002; MacGowan et al., 1997; Pulverenti et al., 2002).  
However, length of stay data does not indicate whether the prolonged hospitalization is a 
risk factor or a consequence of CDAD.  Three studies suggest that a prolonged hospital 
stay increases risk for the disease.  Significant positive multivariate associations have 
been reported for prolonged post-operative hospital stay (Harbarth, Samore, & Carmeli, 
2001), hospitalization greater than or equal to eight days during a risk period (Pulvirenti 
et al., 2002), and hospitalization more than ten days in the month preceding infection 
(Pulvirenti et al., 2002).  Although an increasing length of stay increases exposure to 
microbes in the environment, its sensitivity and specificity as a measure of CDAD risk is 
uncertain.  It may represent a confounder, rather than a risk factor. 
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Modena et al. defined severity of illness in terms of both mechanical ventilation 
and the need for care within an intensive care unit (ICU) (2005).  Mechanical ventilation 
use had a significant positive association with CDAD in univariate analysis and an ICU 
stay was statistically significant in multivariate analysis.  This categorical data lacks 
precision.  Like length of hospital stay, it may represent a confounding variable rather 
than a risk factor. 
McFarland (1995) provided the earliest publication in this review to use the Horn 
Severity of Illness Index as a measure.  Statistically significant differences in severity 
index score were reported within the publication.  Relative risks calculated from 
published data found a statistically significant positive association for the catastrophic 
level of illness, but not for the severe level.   Kyne (2002) reported statistically significant 
positive associations for both the catastrophic and severe levels of illness.  Kyne also 
examined the predictive value of the instrument with a score of three or more and 
reported sensitivity 79-87, specificity 39-73, positive predictive value 11-27 and negative 
predictive value 96-97.  More recently, Vesta (2005) published study data that enabled 
calculation of a statistically significant O.R. of 7.67 for catastrophic illness.  There is 
strong evidence that illness that weakens the body’s immune system increases the risk of 
CDAD.  Although still a categorical measure of severity of illness, the Horn Index 
presents a more precise measure of risk than a simple binary variable. 
Use of a measure such as the Horn index is more appropriate in the development 
of an ecological model for the study of CDAD that is relevant to nursing practice.  Such 
an instrument attempts to quantify the human response to illness, rather than labeling the 
disease process.  
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Ecological Model for Study of CDAD 
The conceptual model for this study is derived from a model created for the study 
of ecosystems as they affect human health (Koren & Crawford-Brown, 2004).  This 
model considers the macroenvironment, the external environment within which a 
potential host functions, and the microenvironment, the physiological factors that alter 
the susceptibility of the host.   
The movement of human beings within the healthcare setting creates 
environmental stressors that can lead to contact, or exposure, between a potential host 
and a potentially infectious microorganism. Exposure, however, does not automatically 
result in disease for several reasons.  First, the amount of exposure an individual sustains 
is influenced by the degree of temporal and spatial distance between the area of 
contamination and the human being.  Extrinsic risk factors, such as antibiotic usage 
policies, infection control compliance, and the use of standardized cleaning procedures 
are designed to increase the temporal and spatial distance between microorganisms and 
humans.  Second, and perhaps more importantly, the host response is dependent upon 
intrinsic factors that modulate the immune response through changes in the 
microenvironment.  In the case of CDAD, specific factors known to have substantial 
evidence for an association with CDAD are severity of illness, changes in the microflora 
of the gut due to aging, antibiotic or chemotherapy usage, use of enteral feeding systems, 
malnutrition, gastric acid suppression, and preoperative bowel preparation regimens.  An 
exposed individual will respond to Clostridium difficile exposure by forming antibodies, 
becoming an unprotected carrier, or by developing active Cd infection in varying degrees. 
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HUMAN ACTIVITY WITHIN HOSPITAL MACROENVIRONMENT 
Environmental cleaning and disinfection 
Movement of healthcare workers 
Visitation 
Admission of patient 
 
 
ENVIRONMENTAL STRESSORS 
Environmental contamination with  Clostridium difficile organism 
 
 
EXPOSURE 
 
 
ENVIRONMENTAL SYSTEMS AFFECTING HOST RESPONSE  
Extrinsic Intrinsic 
Spatial and temporal distance from 
microorganisms influenced by: 
Antibiotic restriction policies 
Infection control compliance 
Tube feeding systems 
Persistence of spores 
Severity of illness 
Age 
Antibiotic exposure 
Enteral feeding 
Malnutrition 
Cathartic administration 
Gastric acid suppression  
 
 
RESPONSE TO EXPOSURE 
Infection Continuum 
Protected 
Carrier 
Unprotected 
Carrier Mild CDAD 
Persistent 
CDAD PMC 
 
 
EXCRETION 
 
Figure I.  Model for the study of ecological variables affecting development of 
Clostridium difficile-associated diarrhea. 
 
This study will focus only on the portion of the model that considers the intrinsic 
and extrinsic factors that affect a host response to Cd exposure.  Because the Cd organism 
can persist in an environment for prolonged periods of time in its spore state, reliance 
solely upon extrinsic environmental factor to stop the infection may not be sufficient.  
Despite nearly two decades of widespread use in the developed world of personal 
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protective equipment for the handling of all potentially infectious material, as well as 
national campaigns to promote handwashing and judicious antibiotic usage, outbreaks of 
CDAD continue.  Therefore, an alternative means of identifying the most susceptible 
hosts and providing ecologically based care may present of more effective means of 
controlling this disease. 
Summary 
This review of literature has identified ecological variables that affect the 
response of a hospitalized adult exposed to the Cd organism.  These variables will be 
used in the design of a case-control study to identify an ecological model useful for 
nurses.  These variables include age, antibiotic exposure, bowel preparation, enteral 
feeding, malnutrition, gastric acid suppression, and severity of illness.   
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Chapter Three 
Research Methods 
Research Design 
The purpose of this study was to develop and test a predictive model for the 
development of Clostridium difficile-associated diarrhea.  It is anticipated that such a 
model can serve three purposes:  (1) serve as a foundation for development of a valid and 
reliable risk assessment tool (2) aid in the design of future clinical trials of nurse-directed 
prevention strategies, and (3) assist clinicians in modifying infection control practices in 
institutional settings when caring for high-risk individuals.  The study used a case-control 
design to develop a predictive model to identify ecological risk factors most closely 
associated with the development of hospital-acquired Clostridium difficile associated 
diarrhea. 
Setting 
The setting was a Veteran’s Administration Medical Center located in the 
state of Florida.  The Medical Center is a 327 bed tertiary care teaching hospital, 
with 300 additional authorized nursing home care beds and serves an estimated 
population of 435,442 veterans. The full range of inpatient and outpatient care is 
provided including Medicine (111 beds), Surgical (61 beds), Psychiatry (50 beds), 
Neurology (7 beds), as well as a 60-bed Spinal Cord Injury Service, and a 38-bed 
Comprehensive Rehabilitation Center. The center also provides a number of 
outpatient clinics on site and at satellite locations. 
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The Center is affiliated with a University College of Medicine and 
provides residency training programs in the following specialties: Internal 
Medicine, Orthopedics, Hematology, Pathology, Radiosurgery, Ophthalmology, 
Dermatology, Podiatry, Neurology, Neurosurgery, Urology, Nephrology, General 
Surgery, Otolaryngology, Psychiatry, Radiology. 
Sample 
The study sample consisted of 66 cases and 66 matched controls for a total of 132 
subjects.  Cases and controls were selected from the electronic medical record database of 
the study site medical center.  Electronic medical records generated between January 1, 
2000 and December 31, 2006 were utilized.  Figure 2 illustrates the sequential steps used 
in selecting the cases, selecting potential controls, and matching controls to cases. 
A total of 1,739 medical records were selected by data mining the medical records 
database.  Criteria specified for the data mining were  
(1) inpatient hospital admission between January 1, 2000 and December 31, 2006 
and  
(2) laboratory studies for Clostridium difficile cytotoxin assay, total lymphocyte 
count, serum albumin, and serum pre-albumin level documented during this time frame.   
Of the 1,739 records, 330 were selected as potential cases from the original group 
because they also had a medical record diagnostic coding for Clostridium difficile 
associated diarrhea.  Within this set, 155 records were identified which met the inclusion 
criteria of hospital acquired infection as defined by a diagnosis made > 2 days after 
hospital admission and < 31 days after hospital discharge, the cut-points selected for 
determination of a hospital-acquired CDAD. 
47 
1,737 records selected for screening based on presence of laboratory testing for 
Clostridium difficile, serum albumin, serum prealbumin and total lymphocyte count 
between January 1, 2000 and December 31, 2006. 
 
 
330 records selected for further 
screening with diagnostic coding for 
CDAD 
 1,636 records selected for further 
screening using criteria of “no 
positive Clostridium difficile test 
 
 
155 records with diagnostic code 
entered ≥ 2 days after admission and 
≤ 31 days after discharge 
 Temporal matching.  Records 
selected if hospital admission date + 
31 days of one or more cases 
 
 
106 records met diagnostic criteria 
for SHEA and had no 
documentations of any medical 
conditions specified for exclusion 
from study 
 Spatial matching.  Records selected 
if admission unit OR unit with 
greatest length of stay matched one 
or more cases. 
 
 
6 records deleted due to sub-acute 
stay > 150 days for total of 100 
potential cases 
 Potential matches screened for 
presence of diarrhea, absence of 
other diagnostic testing suggestive of 
CDAD and absence of the exclusion 
criteria 
 
 
66 cases matched 71 controls, with 4 controls each 
matching 2 different cases 
 
 
Controls with admission date closest to case 
selected for final sample 
• 66 cases 
• 66 controls 
 
Figure 2.  Sample selection process. 
 
The set of 155 medical records was examined to determine if the record was 
consistent with criteria for CDAD case definition outlined in the Shea Position Paper 
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(Gerding, Johnson, Peterson, Mulligan, & Silva, 1995).  These criteria were (1) diarrhea  
(2) documented concurrently or within 7 days of a positive result on one or more of the 
following diagnostic tests: 
• Endoscopy with confirmation of pseudomembranous colitis 
• Stool culture for toxigenic strain of C. difficile 
• Cell culture cytotoxin test 
• EIA toxin test 
To reduce selection bias that might occur in persons tested for C. difficile due to 
recurrence of diarrhea following a previously diagnosed infection, cases were excluded if 
the database included a diagnosis of CDAD within 12 months preceding the positive test 
result.  Because persons with chronic diarrhea referred for stool testing may experience 
colonization with C. difficile and might be easily misclassified, cases were also excluded 
if there was a history of any of the following: surgical removal of sufficient bowel to 
result in chronic diarrhea, chronic ulcerative colitis not previously subjected to surgical 
cure, Crohn’s disease, diarrhea-predominant irritable bowel syndrome, or diabetic 
neuropathy with chronic diarrhea. 
The screening process identified 106 medical records that qualified for inclusion 
in the study.  Because the focus of the study was acquisition of CDAD during acute care 
hospitalization, records also were examined for length of stay in sub-acute areas of the 
institution.  Six records were discarded due to sub-acute length of stay in excess of 150 
days.  This yielded a final set of 100 cases. 
A total of 1,636 records in the Access database were screened for selection of 
controls.  These 1,636 records were based on a query to identify records that never 
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recorded a positive C. difficile assay.  Because ecological disease models consider both 
temporal and spatial distance to be a factor in the spread of communicable disease, 
controls were matched to cases by hospital admission date and geographic unit of 
hospital.  For purposes of matching, when a record indicated that the subject was treated 
in more than one unit, the unit with the longest length of stay was used for spatial 
matching. To select the potential cases, records were first matched based on admission 
date + 31 days using an Access query.  Records were then manually inspected to match 
potential controls to cases by admission unit or unit with the longest length of stay.  
Records that matched a case for both admission date and geographic unit of the hospital 
were reviewed to ensure presence of the following: (1) diarrhea documented within 7 
days of the Clostridium difficile assay test,  and (2) absence of both endoscopy and stool 
culture results indicative of CDAD.  A total of 71 records were identified as matches.  
Within the 71 records, there were 4 duplicate matches.  To enable a 1:1 matching, the 
control record that most closely matched the case record admission date was selected for 
the study.   
Measurement of Variables 
Age 
Age of subjects was recorded as the chronological age in years, on the date of 
hospital admission. 
Nutritional Status 
Nutritional status was measured through use of three continuous variables: serum 
albumin, serum prealbumin, and lymphocyte count.  Laboratory values were recorded 
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only for specimens collected within seven days of hospital admission.  Laboratory 
reference ranges for these tests at the research site are identified in table 4. 
Table 4 
Laboratory Reference Ranges for Nutritional Indicators 
Test Low High 
Pre-Albumin (mg/100 ml) 18 45 
Albumin (mg/100 ml) 3.8 4.8 
Lymphocyte count (109/L) 1.1 3.4 
 
Antibiotic Burden 
Antibiotic burden was calculated for each subject by antibiotic agent, as a 
numerical sum of all Defined Daily Doses.  The Defined Daily Dose is the assumed 
average maintenance dose per day for a drug when it is used for its main indication in 
adults with normal organ function.  This measure was developed for the World Health 
Organization (WHO) Collaborative Centre for Drug Statistics Methodology to enable 
measurement of drug consumption independent of formulation or price.  All DDD 
calculations were calculated using the WHO index on the world-wide web at 
http://www.whocc.no/atcddd/.  For each antibiotic agent administered, data was recorded 
from the electronic record regarding the prescribed dose of the drug and the number of 
doses admininstered during the length of the exposure period (hospital admission to date 
of CDAD testing).  These prescribed doses were then converted to DDD units, and a sum 
of the DDD units was computed for each drug.  The drug burden for each subject was the 
sum total of all DDD’s for all antibiotic agents. 
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Laxatives and Bowel Preparation Medications  
Use of any cathartics administered orally or via a feeding tube for either (a) bowel 
cleansing regimens prior to surgical or endoscopic procedures or (b) prevention or 
treatment of constipation were recorded in a manner similar to antibiotics, and a DDD 
was calculated for each subject.  Bowel preparations were excluded if there was 
documentation in the medical record indicating administration for a diagnostic procedure 
to identify pseudomembranous colitis in an individual believed infected with Cd.  
Gastric Acid Suppression 
Gastric acid suppression was measured for each subject by drug, dosage, dosage 
units, and number of dosages administered between the date of hospital admission and 
the date a stool sample was submitted for CDAD testing.  This information was then 
converted to Defined Daily Doses (DDD), and a sum of the DDD units was computed.  
For comparison purposes, drugs classified as proton pump inhibitors and those classified 
as histamine-2 blocking agents were recorded separately and DDD units were calculated 
as separate categories. 
Enteral Feeding 
Enteral feeding was measured by the number of days in which a nasogastric, 
nasoenteral, or percutaneously inserted enteral feeding tube was used to provide 
nutritional support between the date of admission and the date a stool sample was 
submitted for CDAD testing.   
Severity of Illness  
Severity of illness level was assigned by the principal investigator using the 
Severity of Illness index (Horn & Horn, 1986).  This index is an instrument designed to 
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create a generic measure, independent of clinician practice patterns, which quantifies a 
patient’s illness severity based on retrospective review of records at the time of discharge.  
The index groups patients within a four-level ordinal scale, with one representing the 
least severe and four the most severe illness.  The scale is applied to seven different 
dimensions: stage of principal diagnosis, complications, interactions, dependency, non-
operative procedures, the rate of response to therapy, and the degree to which acute 
symptoms are resolved at the time of discharge and the overall severity score is the modal 
score for the seven categories.  Data from 18 different hospitals found an overall 
weighted interrater reliability of 93.5%.  The index has been found to explain 69-87% of 
the variability in resource use within Diagnostic Related Groups (DRGs) and when used 
to adjust for DRGs predicts 61% of the variability in cost per case.  Kyne et al. (2002) 
reported a sensitivity of 87, specificity of 39, positive predictive value of 11 and negative 
predictive value of 97 for a Horn’s index of 3 or more (severe or catastrophic illness) 
when used with a cohort of hospitalized adult patients receiving antibiotics.  In a second 
cohort used to validate the model, the team reported sensitivity of 79, specificity of 73, 
positive predictive value of 27 and negative predictive value of 96. 
Procedures 
Approvals 
Approval to conduct this study was obtained from the University of South Florida 
Institutional Review Board and the James A. Haley VAMC Human Subjects Research 
and Development Committee.  Request was obtained from both boards to waive informed 
consent.  To protect the privacy of all subjects, electronic medical records were de-
identified prior to the start of data collection.  A member of the medical staff of the 
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VAMC, who served on the dissertation committee, performed downloading of potential 
records into an Access database prior to accession by the principal investigator.  Each 
record was then assigned a unique pointer number that was a computer-assigned 
sequential number, having no association with identifying data.  A code-breaking log of 
subjects was retained by the VAMC employee within a locked office in a secured area of 
the medical center until data collection and analysis was completed.  The log was then 
destroyed according to VAMC procedures. 
Validation of Data Collection Procedure 
At the start of data collection, a sample of ten electronic medical records was 
selected and data recorded using an Excel workbook developed by the principal 
investigator.  To validate the accuracy of the principal investigator (PI) in use of the 
electronic medical record system, the VAMC co-investigator also reviewed the same 
records.  The workbook of the PI and co-investigator were compared for concordance of 
data elements.  All discrepancies between the data were clarified and reviewed until 
100% concordance was obtained between the two sets of data.  The PI then developed 
data collection reference guidelines to ensure consistency during the remainder of the 
data collection process. 
Data Collection 
All data were retrieved from the electronic medical record and recorded in an 
Excel workbook developed by the principal investigator based upon a paper worksheet 
previously approved by the dissertation committee.  The worksheet listing all data 
elements collected is in Appendix A.  The written data collection reference guide is found 
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in Appendix B.  All medical record data was recorded under the unique identifier number 
developed in the initial data-mining operation.   
Data Analysis 
The Statistical Package for Social Sciences (SPSS), version 15 software was used 
for all data analysis.  Initial inspection of data revealed missing values for the variables 
prealbumin and albumin.  Because more than one-third of the subjects were missing 
prealbumin data, this variable was not utilized in the statistical analysis.  Missing values 
for albumin were imputed by use of the mean for each group.   
Cross tabulation revealed that 25% of the cells for the variable severity of illness 
included fewer than 5 subjects.  To increase power of the analysis, the four categories of 
the severity of illness variable were collapsed into two: mild/moderate and 
severe/catastrophic.  However, this process resulted in 31 uninformative pairs, and the 
decision was made to retain all four categories of severity of illness for the remainder of 
the data analysis. 
Data were entered into SPSS as a sample of 66 pairs, with the cases coded as 1 for 
outcome and controls coded as 0.  For each covariate, the difference between case and 
control values was computed, and the difference scores were used as the covariates in 
performing logistic regression analysis (Hosmer & Lemeshow, 2000).  Conditional 
logistic regression was then performed using the Cox regression procedure, with data 
stratified by the matched pairs.  Both univariate and multivariate logistic regression 
analysis were performed for all covariates using a forced entry method.   
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Chapter Four 
Results 
This chapter presents the findings from the study.  Following description of the 
cases and controls, results of analytical testing, including the logistic regression 
modeling, is presented. 
Sample 
The data mining and screening process yielded a sample of 66 pairs matched for 
admission date and geographic location within the hospital.  The sample was 98% male 
(64 cases and 65 controls), consistent with the veteran population from which the sample 
was selected.  The age range for cases was 46.48 to 88.6 years, while control age range 
was 31.4 to 90.7 .   The majority of the sample had exposure to antibiotic (83%) and 
proton pump inhibitor (65%) drugs, however there was limited exposure to tube feeding 
(17%) and histamine-2 blocking agents (14%) in this sample.   Subjects were treated in a 
variety of patient care units within the institution, with the majority of the matched pairs 
treated in medical-surgical units, rather than critical care or rehabilitation oriented 
setttings. 
 Subjects were classified in all categories of severity of illness, with the largest 
portion (45%) classified as having moderate illness and a third of the sample (33%) 
experiencing major illness.  Although only 6 subjects (16%) experienced catastrophic 
illness, 4 of these 6 subjects were classified as cases. 
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Approximately half the sample had lymphocytopenia, present in a slightly higher 
percentage of cases (59%) than controls (45%).  Hypoalbuminemia was present for 58% 
of both groups.  Lymphocyte count and serum albumin values correlated significantly 
(Spearman’s rho= .409, p<.01). 
A comparison of means was computed for all continuous variables via paired t-
tests.  There was a statistically significant difference between means (p<.01) for all 
variables except histamine 2 burden and tube feeding days.  Tube feeding days was 
significant at p<.05, and histamine 2 burden was non-significant.  Table 5 identifies the 
variables, means and results of the paired testing for each of these variables. 
Table 5 
Comparison of Case and Control Means Scores on Continuous Predictors 
Predictor 
Cases 
(n=66) 
Controls 
(n=66 t p 
Length of exposure/risk period 
 
17.65 24.77 -9.80 .000 
Laxative/bowel prep burden 
 
6.68 6.12 -3.43 .001 
Proton Pump Inhibitor burden 
 
8.81 15.56 -7.53 .000 
Histamine 2 burden 
 
2.02 1.29 -2.94 .769 
Antibiotic burden 
 
16.95 15.42 -6.70 .000 
Tube feeding days 
 
4.12 4.97 -2.17 .032 
Serum albumin 
 
3.72 3.58 -30.93 .000 
Total lymphoncyte count 
 
1.24 1.12 4.25 .000 
Age 68.47 71.27 -66.77 .000 
 
Temporal and Spatial Clustering 
Examination of the number of cases by unit by month revealed no patterns 
suggestive of an institution-wide outbreak during the time frame of the study.  There 
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were 7 instances of temporal and spatial clustering of cases identified.  Four of the 7 
clusters occurred on the same medical nursing care unit.  All of the clustering occurred 
during the months of March through August in different years.  This temporal and spatial 
clustering underscores the importance of the macroenvironment in the spread of this 
disease. 
Univariate Analysis 
Table 6 illustrates results of the univariate logistic regression for host, 
microenvironmental and macroenvironmental characteristics for both cases and controls.   
Table 6 
Sample Description and Predictors of Hospital Acquired CDAD 
Group Univariate logistic regression 
Characteristic 
Total 
(N=1
32) 
Controls 
(n=66) 
Cases 
(n=66) OR 
95% CI 
Lower   Upper p 
Host characteristics 
Age (years)        
 M 69.87 71.27 68.47 1.013 .997 1.029 .124 
 SD 11.69 10.28 12.88     
Severity of illness        
 % minor illness 16.67 25.76 7.58 1.845 1.322 2.574 .000 
 % moderate illness 45.45 54.55 36.36     
 % major illness 33.33 16.67 50.00     
 % catastrophic illness 4.54 3.03 6.06     
Serum albumin (mg/dl)        
 M 3.65 3.65 3.65 0.863 .752 .989 .034 
 SD 0.73 0.72 0.74     
 % hypoalbuminemic 57.58 57.58 57.58     
Lymphocytes         
 M 1.18 1.12 1.24 0.915 .735 1.139 .424 
 SD 0.74 0.77 0.72     
 % lymphocytopenic 52.27 45.45 59.09     
Macroenvironmental characteristic  
Length of exposure (days)        
 M 21.21 24.77 17.65 1.008 .999 1.018 .085 
 SD 23.03 26.21 18.87     
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Table 6 (Continued) 
 Group Univariate logistic regression 
Characteristic 
Total 
(N=1
32) Controls 
(n=66) 
Cases 
(n=66) OR 
95% CI 
Lower   Upper p 
Microenvironmental exposure characteristics 
Laxatives/preps        
 M 6.40 6.12 6.68 .999 .989 1.009 .851 
 SD 16.44 15.98 17.01     
 % exposed (>1DDD) 31.82 31.82 31.82     
Proton pump inhibitors         
 M 12.18 15.56 8.81 1.017 1.002 1.032 .023 
 SD 18.20 21.72 13.13     
 % exposed (>1DDD) 65.15 65.15 65.15     
Histamine 2 blockers         
 M 1.65 1.29 2.02 .990 .961 1.020 .516 
 SD 5.98 4.22 7.35     
 % exposed (>1DDD) 14.39 15.15 13.64     
Antibiotic burden        
 M 16.18 15.418 16.95 1.002 .994 1.010 .684 
 SD 25.14 24.642 25.804     
 % exposed (>1DDD) 78.03 72.73 83.33     
Tube feeding (days)        
 M 4.55 4.97 4.12 1.002 .991 1.012 .768 
 SD 16.10 17.37 14.85     
 % exposed (>1day) 17.42 16.67 15.15     
 
This analysis identified age, severity of illness, serum albumin level, length of exposure, 
and proton pump inhibitor drug burden as statistically significant predictors of case status 
(p<.25).   
Multivariate Analysis and Model Evaluation 
Conditional logistic regression analysis via a Cox regression procedure was used 
to identify predictor variables significantly associated with classification of CDAD case 
status.  Following an initial modeling process, only three variables remained as 
significant predictors of case status:  severity of illness, antibiotic exposure, and length of 
exposure/risk period.  Table 7 presents the results of the conditional logistic regression 
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modeling.  Increased severity of illness, a decrease in the number of Defined Daily Doses 
of antibiotic, and an increase in the length of hospitalization prior to symptom 
development were all significantly associated with CDAD case status.  The overall model 
was significant at p=.000. 
The calculated Hosmer and Lemeshow estimation of R2 was 25.274, indicating 
that the model explains approximately 25% of the variance in CDAD outcome.  It should 
be noted, however, that “low R2 values in logistic are the norm” (Hosmer & Lemeshow, 
2000, p.167). 
Table 7 
Conditional Logistic Regression of Variables Predictive of CDAD Case Status 
Variable B Wald p OR 95% CI 
Severity of illness .739 13.506 .000 2.094 1.412, 3.106 
Antibiotic exposure -.021 6.007 .014 .979 .962, .996 
Length of exposure .022 5.933 .015 1.022 1.004, 1.040 
Note:  R2 = 25.274 (Hosmer & Lemeshow).  Model χ2 = 23.123, p=.000.  OR= Odds 
Ratio, CI=Confidence Interval. 
 
As covariates were removed from the model, the Odds Ratios (OR) for all other 
covariates remaining in the model were examined to determine if there was a large 
magnitude in the change of the OR which might indicate confounding.  Only one 
clinically significant change was noted.  Both albumin and lymphocyte count appeared to 
serve as slight confounders for the measure of severity of illness, although the magnitude 
of the change in the severity coefficient was small for each variable(5% for serum 
albumin, 3% for lymphocyte count). 
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Following the identification of the initial model, a number of interactions were 
tested via forced entry.  Potential interactions were identified for numerous combinations 
that might be clinically important related to age, serum albumin, antibiotic drug burden, 
and the length of exposure/risk period.  Table 8 lists the interactions tested and the 
outcome of each test.  None of these interactions was found statistically signficant. 
Table 8 
Conditional Logistic Regression of Interaction Effects as Predictors of Case Status 
Interaction B Wald p OR 95% CI 
Age x Antibiotics -.021 .076 .783 .980 .846,1.135 
Age x Albumin .156 .018 .893 1.169 .120, 11.414 
Age x Lymphocytes .116 .008 .927 1.123 .094, 13.432 
Age x Laxatives .000 .034 .853 1.00 1.00, 1.00 
Age x Proton pump inhibitor .031 .076 .783 1.031 .8289, 1.283 
Age x H2 blocker      
Age x Length of exposure -.015 .038 .846 .985 .844, 1.149 
Albumin x Lymphocyte 2.520 .018 .893 12.431 .000, 1E+017 
Albumin x Proton pump 
inhibitor .426 .376 .540 1.532 .392, 5.984 
Albumin x Length of exposure -.194 .076 .783 .824 .207, 3.275 
Antibiotics x Albumin -.425 .250 .617 .654 .123, 3.460 
Antibiotics x H2 blockers -.076 .403 .526 .926 .732, 1.173 
Length of exposure x 
Lymphocytes -.195 .038 .846 .823 .116, 5.859 
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DFBeta residuals were examined to identify data points that may have been 
unduly influential for a particular covariate or which did not fit the model well.  All of 
these residuals were very small (< 0.06). 
Collinearity was assessed via generation of a matrix of correlations, using the 
non-parametric Spearman rho.  Statistically significant correlations were all of low 
magnitude (<.50) except for the correlations between length of exposure with antibiotic 
burden (.541, p=.000) and tube feeding days with antibiotic burden (.513, p=.000).  
Collinearity diagnostics in the linear regression function revealed no tolerance values < 
0.1 and no VIF values > 10, indicating that there were no serious problems with 
collinearity caused by these correlations. 
Receiver Operator Characteristic (ROC) curves were generated for each of the 
predictors in the model.  Figure 3 illustrates the plot of sensitivity versus 1-specificity for 
the Severity of Illness index for all possible cut points.  The area under the curve is .776, 
indicating an acceptable level of discrimination.  The area under the curve for length of 
exposure was less acceptable at .620.  The plot for antibiotic burden was nearly non-
discriminatory with an area under the curve of .537.   
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Figure 3.  ROC curve for Severity of Illn ss index. Area under the curve = .776. 
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Figure 4.  ROC curve for length of exposure.  Area under curve =.620. 
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Figure 5.  ROC curve for antibiotic burden.  Ar a under curve = .537.   
Hypothesis 
The study originally hypothesized that severity of illness, length of exposure and 
malnutrition are significant predictors of CDAD cases status when cases and controls are 
matched for admission date, and geographic unit of hospital, and after controlling for the 
effects of age, tube feeding, cathartic administration, antibiotic therapy, and acid 
suppression therapy.  This sample suggests that both severity of illness and length of 
exposure are significant predictors, but that malnutrition estimated by two laboratory 
indicators, serum albumin and lymphocyte count, is not an accurate predictor.  It was 
anticipated that antibiotic exposure might represent an effect modifier, rather than a 
predictor.  However, antibiotic exposure, quantified by cumulative Defined Daily Doses 
was identified as a significant independent predictor of CDAD case status and failed to 
demonstrate any interaction effects when tested in combination with a number of 
biologically plausible covariates. 
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Chapter Five 
Discussion 
The purpose of this study was to test an ecological model for its usefulness in 
predicting the development of Clostridium difficile-associated diarrhea in hospitalized 
adults.  This chapter discusses the findings of the study, conclusions about the findings, 
limitations of the study, and implications for nursing practice and education, as well as 
future nursing research. 
Based on an ecological model, it was hypothesized that severity of illness, length 
of exposure and malnutrition would significantly predict the development of CDAD case 
status when cases and controls are matched for admission date, and geographic unit of 
hospital, and after controlling for the effects of age, tube feeding, cathartic 
administration, antibiotic therapy, and acid suppression therapy. 
Severity of Illness 
Although the portion of the sample rated as catastrophic on the Severity of Illness 
Index was less than 20%, the portion of cases rated as catastrophic was double that of 
controls.  An even greater disparity was observed in the category of major illness, with 
50% of cases and only 16.67% of controls exhibiting characteristics of major illness.  
More than 80% of controls fell into either moderate or minor severity of illness 
categories, but only less than 45% of cases were similarly ranked.   
Severity of illness was identified as a statiscally significant independent predictor 
of CDAD case status for this sample following conditional logistic regression analysis.  
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This finding is consistent with previous studies using the Horn Severity of Illness index 
(McFarland, 1995; Kyne, 2002; Vesta, 2005).  Likewise, it is consistent with the work of 
Modena (2005) who characterized severity in relation to events such as mechanical 
ventilation and ICU utilization, criteria that are part of the Horn Severity index. 
Length of Exposure 
Length of exposure was defined as the number of days which elapsed from the 
date of hospital admission until the submission of a stool sample for Clostridium difficile 
laboratory testing.  This variable was derived for this study from the ecological model 
specifying extrinsic ecologic factors affecting infectious disease exposure.  Based on the 
model, both temporal and spatial distance must be increased to prevent the transmission 
of microbial contaminants to susceptible hosts.  Previous researchers have considered 
length of total hospital stay as a variable, but this was studied primarily as a proxy for 
severity of illness.  The author is unaware of previous studies considering temporal 
distance as a risk factor for acquisition of this disease.   
In this study, there was a statistically significant difference between the mean 
length of exposure for cases and controls (17.65 versus 24.77 days).  Length of exposure 
was also identified as a statistically significant independent predictor of CDAD case 
status following multivariate modeling.  Specifically, the longer a subject had been 
hospitalized prior to the development of diarrhea and subsequent stool sample collection, 
the more likely that the diarrhea was caused by Clostridium difficile.   
Malnutrition 
This study attempted to operationalize malnutrition by means of three commonly 
available laboratory tests:  serum albumin, lymphocyte count, and serum prealbumin.  
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Since immunocompetence is partially dependent upon positive nitrogen balance and 
intake of essential vitamins and minerals, it was hypothesized that malnutrition, 
evidenced by values below the laboratory’s reference values, would be associated with 
CDAD status.  Although the original data mining process used prealbumin test results as 
one of the criteria for selection of a record for screening, only a small number of the 
records included prealbumin test results during the same hospitalization as the diarrhea 
episode.  Therefore, this variable could not be included in the analysis. 
Between cases and controls, identical proportions of subjects demonstrated 
hypoalbuminemia, while a greater proportion of cases than controls exhibited 
lymphocytopenia based on the laboratory’s reference values for each test.  However, in 
this sample, cases demonstrated significantly higher mean albumin and lymphocyte 
values than cases.. 
Lymphocyte count was not significantly associated with CDAD status in either 
univariate or multivariate analysis.  Serum albumin was associated on univariate analysis 
with CDAD case status, but failed to demonstrate a significant association during 
multivariate analysis.  The univariate association is consistent with other reported 
univariate associations between serum albumin and CDAD (Al-Tureihi et al., 2005, 
Andrews et al., 2003, Raveh, Rabinowitz, Breuer, Rudensky, & Yinnon, 2006; Rubin et 
al., 1995).  Recently, a significant multivariate association was reported between 
hypoalbuminemia and CDAD (Peled et al., 2007).  In that study, a significant difference 
existed between mean albumin scores of cases and controls, and subjects were 
categorized for the logistic regression analysis based on a selected cut-point to indicate 
hypoalbuminemia.  The data group in this present study also exhibited a statistically 
67 
significant difference in mean albumin scores between cases and controls on univariate 
testing with a paired t-test.  It should be noted that in this sample, identical proportions of 
cases and controls had serum albumin levels lower than the laboratory reference low 
value of 3.8 mg/100 ml.  Only 26% of the entire sample had albumin levels lower than a 
value of 3.4 mg/100 ml.  
Age 
This sample demonstrated a statistically significant difference between the mean 
age of cases and controls, but failed to produce an independent association between age 
and CDAD status on multivariate analysis.  This finding is in contrast to the substantial 
support in the research literature for advancing age as a risk factor for CDAD (Bignardi, 
1998).  The sample in this study was relatively heterogeneous in terms of age, and this 
represents a departure from samples in other studies.  This broader range of subject ages 
may be a reflection of the specific Veteran’s Administration Medical Center population 
from which the sample was drawn. 
Microenvironmental Exposure Variables 
This study included a number of exposures previously identified in the literature 
as affecting the bacterial ecology of the intestinal tract.  These exposures included 
laxative or cathartic drugs, acid suppression drugs, antibiotics, and tube feeding.  It was 
hypothesized that these variables would not be significant predictors of CDAD status in a 
study design that carefully considered criteria for case and control selection and matched 
for both temporal and spatial exposure data.   
For purposes of this study, an attempt was made to quantify the dose response 
phenomenon for microenvironmental exposure through use of standardized measures.  
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For drug exposure, the World Health Organization’s Defined Daily Doses were computed 
for each class of drug and summed to produce a continuous measure of exposure.  For 
tube feeding, the measure was the number of days of tube feeding prior to the onset of 
diarrhea and stool testing.  Although a number of studies have considered these same 
variables, exposure has often been measured strictly as a dichotomous variable. 
Tube Feeding 
This data failed to demonstrate tube feeding exposure as a significant predictor of 
CDAD.  Although nearly all of the subjects tube fed during the period experienced 
enteral nutrition for more than 2 weeks, there were simply not enough subjects in the 
sample among either cases or controls who received this therapy.  Therefore, there was 
not sufficient power to detect a difference between the two groups. 
Cathartic Burden  
When measured as drug burden based on the total number of Defined Daily Doses 
ingested during the exposure period, cathartic drugs failed to demonstrate a significant 
exposure risk.  Although there was a statistically significant difference between mean 
cathartic drug burdens of the two groups, both univariate and multivariate logistic 
regression revealed non-significant O.R.’s for this variable. 
Acid Suppression Burden   
Acid suppression burden considered the DDD’s for both proton pump inhibitor 
drugs and histamine 2 blocking agents.  Neither category of drug was found to be a 
statistically significant predictor of CDAD when measured this way.  In this sample 
identical or nearly identical portions of both cases and controls had exposure to acid 
suppression therapy, so that even if this variable had been measured as binary data, 
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similar to some previous studies, it is unlikely that it would have proven to be a predictor.  
Although two prospective case-studies have recently reported significant multivariate 
associations for acid suppression, both measured exposure based on subject’s reporting of 
prescribed drugs prior to hospitalization (Peled et al., 2007; Yearsley et al., 2006) and 
thus were subject to recall bias.  Likewise, neither study focused on hospital administered 
acid suppressive drugs, the most meaningful information available to the bedside 
clinician. 
Antibiotic Burden   
This study demonstrated that an increase in antibiotic drug burden actually 
provided a slight decrease in risk of the development of hospital-acquired CDAD.  This 
finding contrasts sharply with other studies, which measure exposure in other terms such 
as the number of drugs, number of prescribed doses, number of days of therapy.  In 
previous research, a dose-response relationship has been demonstrated for antibiotic 
exposure.  The decreased dose-response in this study may have occurred for several 
reasons.  The combined DDD’s of all categories of antibiotics were considered together 
as a group, regardless of the therapeutic or chemical classification of the antibiotic, which 
may account for some of the differences.  Analysis of data by specific drug categories 
may have resulted in some demonstration of increased risk.  Case-control studies, which 
examine specific drugs or drug categories are subject to considerable selection bias, 
particularly in prospective studies in which the drug exposure of interest is used as a 
criterion for study participation.  Drug prescribing patterns vary geographically and 
between different health systems, and the antibiotic formulary available to clinicians 
varies between institutions, making cross comparisons difficult.  It also is possible that 
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antibiotic exposure in some studies may actually represent the confounding factor of 
severity of illness.  The more severely ill individual remains hospitalized longer, thus is 
exposed to more drug therapy overall, and more environmental stressors. 
Limitations of the Study 
A serious limitation of this study was the small sample size obtained for the 
number of variables screened.  A lack of statistical power may have influenced the failure 
to obtain statistical significance for some predictors.  Although the original data pool was 
very large, the screening criteria and matching criteria were very strict to decrease bias 
identified in earlier research.  As a result of this screening and matching process, only 66 
pairs could be identified from the initial 1, 737 records. 
The homogeneity of gender for this sample is also a limitation.  The 
predominance of male subjects is not representative of the general acute care hospital 
population.  The data collection process made no attempt to determine ethnicity of the 
subjects.  Although previous research has not identified any ethnic differences in the 
development of CDAD, it is possible that differences in response to exposures, 
particularly drug exposures may vary based on genomic differences. 
The large number of missing values for the prealbumin variable necessitated 
removal of this variable from any type of statistical modeling.  Elimination of this 
variable, combined with the small number of tube fed subjects, makes it extremely 
difficult to determine the impact of nutritional status on development of CDAD among 
this sample.  Although lymphocyte count provides some information about nutritional 
status, serum albumin is influenced by many biologic factors in addition to nutrition and 
cannot be considered an accurate measure of nutritional status. 
71 
This study used a retrospective case-control design.  Although an attempt was 
made to establish a temporal relationship between exposure and disease by excluding 
subjects hospitalized less than 2 days or discharged more than 31 days before the onset of 
diarrhea symptoms, it is still possible that actual exposure to Clostridium difficile 
microorganisms occurred prior to or after hospitalization.  The design was also 
vulnerable to selection bias, since cases were initially identified via data mining medical 
records to identify those with available data points for four specific laboratory tests, one 
being the toxin assay for the disease.  Therefore, the clinicians caring for the subjects at 
the time diarrhea symptoms were identified, introduced a form of diagnostic bias into the 
study, which was beyond the control of the researcher.  If a clinician believed that CDAD 
was a possible differential diagnosis, a specimen was likely submitted.  There may have 
been additional potentials subjects with diarrhea symptoms who would have tested either 
positive or negative for CDAD cytotoxin. 
Generalizability 
Given the limitations of the sample and the retrospective case-control design, 
caution should be used in any attempts to generalize these findings to other acute care 
hospital settings.  The lack of female subjects and the constricted age range indicate these 
findings may not be applicable to other settings.  The study site is located in a major 
metropolitan area, with numerous other comprehensive hospitals available.  Given the 
mean age of study participants, Medicare insurance coverage would qualify many of the 
subjects for treatment at any of these other institutions.  It is impossible to know why an 
individual might be hospitalized at a particular institution.  Therefore, it is possible that 
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other host-related variables exist inherently within the veteran’s population, which were 
not measured in this study.   
Implications for Nursing Education and Practice  
This study presents some important implications for nursing education and 
clinical practice.  The framework used to organize the study suggests that if clinicians can 
identify intrinsic host characteristics that make them more susceptible to disease, the 
clinician can alter the external environmental conditions to increase spatial and temporal 
distance between the vulnerable individual and the harmful environmental exposure.  
This study identified increased length of exposure, increased severity of illness, and a 
decrease in antibiotic drug burden as independent predictors of CDAD development 
among hospitalized adults.  As more virulent strains of Clostridium difficile continue to 
emerge, clinicians must develop new strategies for increasing temporal and spatial 
distance beyond the currently employed system of universal precautions combined with 
isolation of infected persons.  Some means of “isolating” will need to occur for the most 
severely ill persons. 
This is particularly evident in the critical care environment, where most patients 
have extensive organ involvement, require multiple means of life support, and have 
complex interrelated pathophysiologic derangements.  Unfortunately,  this is also the 
same environment in which traditional spatial distance is limited by design of the unit and 
temporal distance is rarely possible due to the high demand for critical care bed 
placement in modern hospitals.  Therefore, new strategies may be necessary to achieve 
spatial distance such as strict stool containment and disposal, limitation of caregivers, and 
assignment of infected and non-infected patients to totally different care teams.   
73 
Nurse educators working in both pre-licensure and continuing education settings 
face a number of challenges.  Through contamination of hands, equipment, and uniforms, 
nurses can serve as a vector for transmission of Clostridium difficile spores.  Continuing 
to teach students and practitioners prevention of infectious disease through traditional 
mechanisms of identification and isolation does not fully enable them to appreciate the 
importance of identifying the vulnerable, at-risk population to protect them from 
exposure.  Nurses working in practice settings with clients at high risk for infection, such 
as neonatal and bone marrow transplant units, have demonstrated that limitation of 
visitation, restriction of access to the care unit, and adherence to use of handwashing and 
barrier products can reduce the incidence of infections among high-risk persons.  
Educators teaching about infectious disease need to include content about identification 
of at-risk clients and increasing spatial and temporal distance between at-risk individuals 
and infected individuals. 
Nurse administrators may also need to consider changes in work assignment, 
visitation policies, and the spatial assignment of individual patients.  This will be 
problematic given a global nursing shortage.  However, nosocomial infections may prove 
to be an economic burden that threatens the continued viability of institutions, 
particularly in an era when third party payers are choosing to withhold compensation for 
problems that develop during an individual patient’s stay within an acute care hospital. 
Recommendations for Future Research 
Nurses must become increasingly involved in research concerning the epidemiology and 
prevention of all types of hospital acquired infections to ensure that predictors and 
prevention measures are well grounded and clinically useful. 
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Future research regarding CDAD should include measures to determine if other 
commonly used measures of disease severity or patient acuity might be as useful in 
predicting risk as the Horn Severity of Illness index, particularly tools that are already 
widely used by nurses such as the APACHE II scoring system. 
More research is needed to understand the relationship between drug exposure 
and CDAD.  A prospective, multi-center case-control study would enable accumulation 
of sufficient data points to determine multivariate associations.  There is a definite need 
for a standardized measure of drug exposure.  Although somewhat tedious, this study 
demonstrates that the DDD system is one way in which standardized measures of drug 
exposure could be compared across studies. 
Two recent publications have identified colonization pressure, the sum of daily 
point prevalence rates of disease for each day spent in the environment of exposure, as 
significant predictors of CDAD development (Dubberke et al., 2007; Lawrence et al., 
2007).  Colonization pressure is a quantifiable way to measure the variable of 
environmental stressors identified in the conceptual framework for this study.  
Intervention studies to determine strategies for disease prevention could use this concept 
as an outcome variable.  As a continuous variable, this would offer benefits in study 
design and data analysis over traditional binary outcomes. 
Conclusions 
This study confirmed severity of illness and length of exposure as independent 
predictors of the acquisition of hospital-acquired Clostridium difficile-associated 
diarrhea.  It did not confirm malnutrition as a risk factor as hypothesized.  An increase in 
the number of Defined Daily Doses of antibiotics was found to indicate a slight decrease 
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in disease risk, a departure from previous research measuring drug exposure in other 
ways. 
The study supports the use of an ecologic model to help explain the phenomenon 
of hospital-acquired CDAD and indicates a framework for future research regarding 
intrinsic host characteristics suggesting increased risk, and intervention strategies to 
decrease environmental stressors on the vulnerable host. 
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Data Collection Worksheet 
 
Exclusion Criteria 
NONE of the following located in medical record: 
  Diagnosis of CDAD within 12 months preceding 
hospitalization 
 History of surgically created chronic diarrhea  
 History of Crohn’s disease or untreated chronic ulcerative 
colitis 
 History of diarrhea-predominant irritable bowel 
syndrome 
 Diabetic neuropathy with chronic diarrhea 
 
Inclusion Criteria 
 
 Case  Diarrhea Control 
Diarrhea:  Diarrhea:  
 >2 stools in 24 hours   >2 stools in 24 hours 
 loose and unformed or liquid consistency  
loose and unformed or liquid 
consistency 
 
concurrent or within 7 days of 
positive finding(s) for:  
concurrent or within 7 days of 
negative finding(s) for: 
 
 
Stool culture for toxin-
producing strain of Cd 
 
Date: 
  
Stool culture for toxin-
producing strain of Cd 
 
Date: 
 
 
Cell culture cytotoxin assay 
 
Date: 
  
Cell culture cytotoxin assay 
 
Date: 
 
 
EIA toxin test 
 
Date: 
  
EIA toxin test 
 
Date: 
 
 
Endoscopy with 
pseudomembranous colitis 
 
Date: 
  
Endoscopy with 
pseudomembranous colitis 
 
Date: 
Demographic Data  
Age on date of admission:    Gender:  Male  Female 
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Matching Information 
 Date Unit  Date Unit  Date Unit 
Admit   Transfer   Transfer   
Transfer   Transfer   Transfer   
Transfer   Transfer   Discharge   
Severity of Illness Index 
LEVELS Characteristic 
1 2 3 4 
Stage of Principal 
Diagnosis 
Asymptomati
c 
 
Moderate 
Manifestation
s 
Major 
Manifestations 
Catastrophic 
Manifestation
s 
Complications None or very 
minor 
Moderate – 
less important 
than principal 
diagnosis 
Major – as or 
more 
important than 
principal Dx 
Catastrophic – 
death or major 
permanent 
disability 
Interactions None or 
minor 
Moderate Major Catastrophic 
Dependency Low Moderate Major Extreme 
Procedures (Non-
O.R.) 
Noninvasive 
Diagnostic or 
Minor 
Therapeutic 
Therapeutic or 
Invasive 
Diagnostic 
Nonemergenc
y Life Support 
Emergency 
Life Support 
Rate Prompt Moderate 
Delay 
Serious Delay No Response Respons
e to 
therapy Resolutio
n of Acute 
Symptoms 
Complete Extensive but 
incomplete 
Incomplete 
and Disabling 
No Resolution 
 
Bowel preparation regimen 
 No laxatives or bowel preparation documented 
 Enema  
 Colostomy irrigation 
 Cathartic: 
____________________________________ 
 Cathartic: 
____________________________________ 
  
NO EVIDENCE that prep 
being administered for 
colonoscopy to diagnose 
Pseudomembranous colitis 
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Tube feeding 
  No tube feeding documented 
 Type of tube Number of days 
used  
  percutaneously inserted tube                gastric        
enteral  
 
  nasoenteral tube  
  nasogastric or orogastric tube  
 
Nutritional indices within first 7 days of hospitalization 
Laboratory indicator Lab normal Value Date Hospital 
Day # 
Serum albumin     
Pre-albumin     
Lymphocyte count     
 
Gastric acid suppression 
A 
Drug name 
B 
Category 
C 
Dosage 
D 
DDD 
E 
DDD 
Units 
F 
# Doses 
G 
(E) x (F) 
Burden 
  PPI 
 H2 blocker 
     
  PPI 
 H2 blocker 
     
  PPI 
 H2 blocker 
     
  PPI 
 H2 blocker 
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Antibiotic exposure 
A 
Drug name 
B 
Category 
C 
Dosage 
D 
DDD 
E 
DDD 
Units 
F 
# Doses 
G 
(E) x (F) 
Burden 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
TOTAL ANTIBIOTIC BURDEN  
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Electronic Medical Record Review Protocol  
 
Data Collection Step 
 
Location of Information 
1. Verify that potential subject does not meet exclusion 
criteria 
History and physical 
Admitting diagnosis 
2. Verify that potential subject meets criteria for inclusion 
as either case or control 
Bowel record 
Laboratory data 
Endoscopy data 
3. Record age Patient information 
4. Record gender Patient information 
5. Record dates of admission and discharge Patient information 
6. Record dates of transfer within the facility by room 
number 
Medication Record 
 
7. Complete Severity of Illness Index:  
a. Stage of principal diagnosis at admission = peak 
extent of organ involvement as manifested by the 
patient at admission 
History and physical 
examination findings 
b. Complications = complications of the principal 
diagnosis, or complications that are a direct result 
of the therapy, hospitalization, or accidents that 
arise during hospitalization 
Discharge summary 
c. Interactions = conditions or problems, other than 
the principal diagnosis and complications, that 
have no  
Discharge summary 
d. Physiologic relationship to the principal diagnosis 
or that contributed to or caused the illness 
represented by the principal diagnosis 
History and physical 
Discharge summary 
e. Dependency = degree to which the patient 
requires more than the minimal level of direct care 
for the principal diagnosis.  It includes 
dependency that is a consequence of the principal 
Nursing acuity rating 
Nursing care records 
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Data Collection Step 
 
Location of Information 
diagnosis, complications, and active interactions.  
The rating should be representative of the 
patient’s “most of the time” dependency during 
the entire hospitalization and the degree to which 
“most-of-the-time” level of care is greater than the 
minimum expected for that principal diagnosis. 
f. Non-operating room procedures = peak 
procedural interventions undertaken 
EXCLUDING surgical procedures performed in 
an operating room.  The TYPE of procedure, not 
the number of procedures performed, determines 
the level of this dimension 
Cardiac arrest record 
Mechanical ventilation  
Laboratory  
Diagnostic imaging  
 
g. Rate of response to therapy = response to the 
therapies instituted for the principal diagnosis and 
the impact of complications and active 
interactions on the hospitalization 
Discharge summary 
h. Remission of acute symptoms = extent to which a 
patient still shows evidence of the acute injury or 
illness related to the principal diagnosis, 
complications, or active interactions at the time of 
discharge, excluding preexisting conditions that 
did not change during the hospitalization and for 
which no change was expected 
Discharge summary 
8. Determine if bowel preparation was administered during 
hospital stay, and if so, record the type of preparation 
administered. 
Medication 
administration record 
9. Determine if tube feeding was used during 
hospitalization, and if so, record the number of days 
administered by the appropriate type of feeding tube 
Diet record 
10. Record the laboratory value for the first test completed 
during the hospitalization.  Record the date of specimen 
collection.  To determine the hospital day number, count 
the date of admission as day 1. 
Laboratory record 
11. Determine gastric acid suppression exposure:  
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Data Collection Step 
 
Location of Information 
a. Record drug name in column A Medication Record 
b. Check box for correct drug category in column B.  
c. Record the drug dosage in Column C Medication Record 
d. Record the Defined Daily Dose (DDD) in Column 
D 
 
e. Divide Column C by Column D to determine the 
number of DDD units and record value with two 
decimal places in Column E 
Pocket calculator 
f. Record the number of doses received prior to 
diagnostic testing for Clostridium difficile in 
Column F.   
Medication Record 
g. Multiply the values in Columns E and F with two 
decimal places to determine the drug burden and 
record in Column G. 
Pocket calculator 
h. Add the values of Column G and record the total 
Acid Suppressant burden 
Pocket calculator 
12. Determine the antibiotic exposure  
a. Record drug name in column A Medication Record 
b. Check box for correct drug category in column B. Antibiotic Guide 
c. Record the drug dosage in Column C Medication Record 
d. Record the Defined Daily Dose (DDD) in Column 
D 
Antibiotic Guide 
e. Divide Column C by Column D to determine the 
number of DDD units and record value with two 
decimal places in Column E 
Pocket calculator 
f. Record the number of doses received prior to 
diagnostic testing for Clostridium difficile in 
Column F.  number of doses received during 
hospital days 1-30 only. 
Medication Record 
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Data Collection Step 
 
Location of Information 
g. Multiply the values in Columns E and F with two 
decimal places to determine the drug burden and 
record in Column G. 
Pocket calculator 
h. Add the values of Column G and record the total 
Antibiotic burden 
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